Unnamed: 0,title,date,stock,sentiment
1326718.0,Vertex Earlier Announced European Commission Approval for KALYDECO for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene,2020-06-10 09:43:00-04:00,VRTX,positive
1326719.0,"The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset",2020-06-10 07:30:00-04:00,VRTX,positive
1326720.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,VRTX,neutral
1326721.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,VRTX,positive
1326722.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,VRTX,neutral
1326723.0,Why Vertex's Stock Is Trading Higher Today,2020-05-15 15:41:00-04:00,VRTX,neutral
1326724.0,Vertex Pharmaceuticals shares are trading higher after Argus Research maintained a Buy rating and raised the price target from $270 to $320.,2020-05-15 15:19:00-04:00,VRTX,positive
1326725.0,"Argus Research Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $320",2020-05-15 10:44:00-04:00,VRTX,neutral
1326726.0,CIRSPR Therapeutics To Present New Data For CTX001 At European Hematology Association Congress Jun. 11-14,2020-05-14 09:22:00-04:00,VRTX,neutral
1326727.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,VRTX,neutral
1326728.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,VRTX,neutral
1326729.0,"Cramer Gives His Opinion On Cisco, Uber And More",2020-05-12 08:33:00-04:00,VRTX,neutral
1326730.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,VRTX,negative
1326731.0,Vertex Pharmaceuticals shares are trading higher after the company and CRISPR were granted Regenerative Medicine Advanced Therapy Designation by the FDA for CTX001 for treatment of severe sickle cell disease.,2020-05-11 11:41:00-04:00,VRTX,positive
1326732.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,VRTX,neutral
1326733.0,"CRISPR Therapeutics, Vertex Pharma Report FDA Granted Regenerative Medicine Advanced Therapy Designation To CTX001 For Treatment Of Severe Sickle Cell Disease",2020-05-11 09:21:00-04:00,VRTX,positive
1326734.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,VRTX,neutral
1326735.0,"Citigroup Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $305",2020-05-01 12:39:00-04:00,VRTX,neutral
1326736.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,VRTX,neutral
1326737.0,Vertex Receives European CHMP Positive Opinion for KALYDECO for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene,2020-05-01 05:35:00-04:00,VRTX,positive
1326738.0,"CFRA Earlier Maintained Buy on Vertex Pharmaceuticals, Raised Price Target to $297",2020-04-30 14:11:00-04:00,VRTX,neutral
1326739.0,"Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $290",2020-04-30 11:14:00-04:00,VRTX,neutral
1326740.0,"BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $283",2020-04-30 10:33:00-04:00,VRTX,neutral
1326741.0,"Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $305",2020-04-30 09:27:00-04:00,VRTX,neutral
1326742.0,"Stifel Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $285",2020-04-30 09:15:00-04:00,VRTX,neutral
1326743.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $277",2020-04-30 08:57:00-04:00,VRTX,negative
1326744.0,"JMP Securities Maintains Market Outperform on Vertex Pharmaceuticals, Raises Price Target to $285",2020-04-30 08:11:00-04:00,VRTX,positive
1326745.0,Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-04-30 07:56:00-04:00,VRTX,positive
1326746.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,VRTX,positive
1326747.0,"HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $295",2020-04-30 07:17:00-04:00,VRTX,neutral
1326748.0,"SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Raises Price Target to $263",2020-04-30 07:02:00-04:00,VRTX,neutral
1326749.0,"Vertex Pharmaceuticals Q1 EPS $2.560 Beats $1.840 Estimate, Sales $1.520B Beat $1.290B Estimate",2020-04-29 16:04:00-04:00,VRTX,neutral
1326750.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,VRTX,positive
1326751.0,"Earnings Scheduled For April 29, 2020",2020-04-29 04:50:00-04:00,VRTX,neutral
1326752.0,Why Vertex's Stock Is Trading Lower Today,2020-04-28 11:48:00-04:00,VRTX,negative
1326753.0,Vertex Pharmaceuticals shares are trading lower after RBC analysts downgraded the company's stock from Outperform to Sector Perform.,2020-04-28 09:41:00-04:00,VRTX,neutral
1326754.0,"Benzinga's Top Upgrades, Downgrades For April 28, 2020",2020-04-28 09:32:00-04:00,VRTX,positive
1326755.0,"RBC Capital Downgrades Vertex Pharmaceuticals to Sector Perform, Raises Price Target to $260",2020-04-28 07:33:00-04:00,VRTX,neutral
1326756.0,"Vertex Reports Multi-Year Collaboration Deal With Affinia Therapeutics For Discovery, Development Of Novel Adeno-Associated Virus Capsids For Genetic Therapies",2020-04-27 08:31:00-04:00,VRTX,positive
1326757.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,VRTX,negative
1326758.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,VRTX,positive
1326759.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,VRTX,positive
1326760.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,VRTX,negative
1326761.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,VRTX,negative
1326762.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-21 10:30:00-04:00,VRTX,neutral
1326763.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,VRTX,positive
1326764.0,Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI and SYMDEKO for Eligible Cystic Fibrosis Patients,2020-04-21 06:06:00-04:00,VRTX,positive
1326765.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,VRTX,neutral
1326766.0,Stocks That Hit 52-Week Highs On Friday,2020-04-17 10:19:00-04:00,VRTX,neutral
1326767.0,Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.,2020-04-16 12:38:00-04:00,VRTX,positive
1326768.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $258",2020-04-15 10:28:00-04:00,VRTX,negative
1326769.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,VRTX,positive
1326770.0,"Cramer Weighs In On Uber, Yelp And More",2020-04-09 08:08:00-04:00,VRTX,neutral
1326771.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,VRTX,neutral
1326772.0,"The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation",2020-04-07 07:55:00-04:00,VRTX,negative
1326773.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,VRTX,positive
1326774.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,VRTX,negative
1326775.0,Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.,2020-03-30 10:17:00-04:00,VRTX,positive
1326776.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,VRTX,positive
1326777.0,10 Stocks To Buy With Low Debt And High Liquidity,2020-03-27 08:15:00-04:00,VRTX,negative
1326778.0,"Vertex Pharmaceuticals shares are trading lower, not currently seeing company-specific news. Movement appears market related as equities experience volatility amid US stimulus progress.",2020-03-25 11:39:00-04:00,VRTX,positive
1326779.0,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",2020-03-24 12:20:00-04:00,VRTX,positive
1326780.0,"Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy $375 billion in treasury this week.",2020-03-23 11:07:00-04:00,VRTX,positive
1326781.0,Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.,2020-03-20 09:43:00-04:00,VRTX,positive
1326782.0,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",2020-03-16 10:50:00-04:00,VRTX,negative
1326783.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,VRTX,negative
1326784.0,10 Biggest Price Target Changes For Wednesday,2020-03-11 08:13:00-04:00,VRTX,neutral
1326785.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,VRTX,neutral
1326786.0,"Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Raises Price Target to $275",2020-03-11 06:27:00-04:00,VRTX,negative
1326787.0,Shares of several healthcare  companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.,2020-03-09 10:55:00-04:00,VRTX,neutral
1326788.0,Vertex Reports Coronavirus Outbreak Has Not Impacted Co.s Supply Chains Or 2020 Business Outlook,2020-03-09 09:52:00-04:00,VRTX,neutral
1326789.0,Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.,2020-03-06 09:11:00-05:00,VRTX,neutral
1326790.0,Shares of several healthcare companies are trading lower. Weakness appears market related as equities across sectors continue to sell off amid coronavirus concerns. NOTE: The sector spiked yesterday following U.S. Democratic primary results.,2020-03-05 10:40:00-05:00,VRTX,negative
1326791.0,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:48:00-05:00,VRTX,positive
1326792.0,Vertex Announces Cancellation Of March 3 Presentation At Cowen Health Care Conference,2020-03-02 15:45:00-05:00,VRTX,positive
1326793.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,VRTX,negative
1326794.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,VRTX,negative
1326795.0,Vertex Reports KALYDECO Now Available In New Zealand,2020-02-25 17:05:00-05:00,VRTX,neutral
1326796.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,VRTX,negative
1326797.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,VRTX,negative
1326798.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,VRTX,positive
1326799.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,VRTX,neutral
1326800.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,VRTX,positive
1326801.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,VRTX,negative
1326802.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,VRTX,neutral
1326803.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,VRTX,negative
1326804.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,VRTX,neutral
1326805.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,VRTX,neutral
1326806.0,Shares of healthcare companies are trading higher amid a rebound in global equities following last week's selloff on coronavirus fears.,2020-02-04 10:08:00-05:00,VRTX,negative
1326807.0,"B of A Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $295",2020-01-31 11:44:00-05:00,VRTX,positive
1326808.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $251",2020-01-31 11:07:00-05:00,VRTX,negative
1326809.0,"CFRA Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $286",2020-01-31 10:52:00-05:00,VRTX,neutral
1326810.0,"RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $260",2020-01-31 10:36:00-05:00,VRTX,neutral
1326811.0,Stocks That Hit 52-Week Highs On Friday,2020-01-31 10:23:00-05:00,VRTX,neutral
1326812.0,"Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $275",2020-01-31 10:16:00-05:00,VRTX,neutral
1326813.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,VRTX,negative
1326814.0,"Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $258",2020-01-31 08:50:00-05:00,VRTX,positive
1326815.0,10 Biggest Price Target Changes For Friday,2020-01-31 08:29:00-05:00,VRTX,neutral
1326816.0,Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company issued FY20 sales guidance above analyst estimates.,2020-01-31 08:12:00-05:00,VRTX,positive
1326817.0,"Baird Downgrades Vertex Pharmaceuticals to Neutral, Raises Price Target to $230",2020-01-31 06:53:00-05:00,VRTX,neutral
1326818.0,Vertex Sees FY20 Sales $5.1B-$5.3B vs $4.87B Estimate,2020-01-30 16:05:00-05:00,VRTX,neutral
1326819.0,"Vertex Pharmaceuticals Q4 Adj. EPS $1.7 Beats $1.2 Estimate, Sales $1.257B Beat $1.01B Estimate",2020-01-30 16:05:00-05:00,VRTX,neutral
1326820.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,VRTX,positive
1326821.0,"Earnings Scheduled For January 30, 2020",2020-01-30 04:59:00-05:00,VRTX,neutral
1326822.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,VRTX,positive
1326823.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,VRTX,neutral
1326824.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,VRTX,neutral
1326825.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,VRTX,neutral
1326826.0,7 Blockbuster Drugs Expected To Be Launched In 2020,2020-01-20 14:18:00-05:00,VRTX,positive
1326827.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,VRTX,neutral
1326828.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,VRTX,negative
1326829.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,VRTX,neutral
1326830.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,VRTX,neutral
1326831.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,VRTX,neutral
1326832.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,VRTX,positive
1326833.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,VRTX,neutral
1326834.0,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",2020-01-09 08:39:00-05:00,VRTX,positive
1326835.0,"Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $265",2020-01-08 11:04:00-05:00,VRTX,neutral
1326836.0,Vertex shares are trading higher after Citigroup raised the price target of the stock from $225 to $265.,2020-01-08 11:02:00-05:00,VRTX,positive
1326837.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,VRTX,positive
1326838.0,Vertex Pharmaceuticals shares are trading higher after PiperJaffray maintained an Overweight rating on the stock and raised the price target from $247 to $284.,2020-01-06 15:45:00-05:00,VRTX,negative
1326839.0,10 Biggest Price Target Changes For Monday,2020-01-06 08:35:00-05:00,VRTX,neutral
1326840.0,"PiperJaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $284",2020-01-06 07:56:00-05:00,VRTX,negative
1326841.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2020",2020-01-02 10:42:00-05:00,VRTX,positive
1326842.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,VRTX,neutral
1326843.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,VRTX,neutral
1326844.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,VRTX,neutral
1326845.0,"JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $247",2019-12-18 09:03:00-05:00,VRTX,neutral
1326846.0,8 Biotech Stocks Morgan Stanley Recommends For 2020,2019-12-17 18:27:00-05:00,VRTX,positive
1326847.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,VRTX,positive
1326848.0,Vertex Announces European Commission Approval For KALYDECO In Infants With Cystic Fibrosis Ages 6 Months To Less Than 12 Months With Certain Mutations In The CFTR Gene,2019-12-10 06:59:00-05:00,VRTX,positive
1326849.0,9 Most Overbought Stocks In The S&P 500,2019-12-09 10:35:00-05:00,VRTX,neutral
1326850.0,Stocks That Hit 52-Week Highs On Friday,2019-12-06 10:33:00-05:00,VRTX,neutral
1326851.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,VRTX,positive
1326852.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-05 10:16:00-05:00,VRTX,neutral
1326853.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,VRTX,positive
1326854.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,VRTX,negative
1326855.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,VRTX,negative
1326856.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,VRTX,neutral
1326857.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,VRTX,positive
1326858.0,Stocks That Hit 52-Week Highs On Monday,2019-11-25 10:19:00-05:00,VRTX,neutral
1326859.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,VRTX,positive
1326860.0,"Bank of America Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to $245",2019-11-20 11:27:00-05:00,VRTX,neutral
1326861.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-20 10:12:00-05:00,VRTX,neutral
1326862.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,VRTX,positive
1326863.0,"Vertex Pharmaceuticals shares are trading higher after the company, along with CRISPR Therapeutics, announced positive, interim data from the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.",2019-11-19 15:43:00-05:00,VRTX,positive
1326864.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-11-19 12:45:00-05:00,VRTX,neutral
1326865.0,Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study,2019-11-19 11:40:00-05:00,VRTX,positive
1326866.0,"Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $229",2019-11-19 10:54:00-05:00,VRTX,negative
1326867.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,VRTX,neutral
1326868.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,VRTX,neutral
1326869.0,CRISPR Therapeutics And Vertex Announce Safety And Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies,2019-11-19 07:10:00-05:00,VRTX,positive
1326870.0,"Molecular Templates Announces Collaboration with Vertex Pharma, Molecular to Receive $38M Upfront Payment Which Includes Equity Investment",2019-11-18 07:10:00-05:00,VRTX,neutral
1326871.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,VRTX,neutral
1326872.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,VRTX,positive
1326873.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-13 10:12:00-05:00,VRTX,neutral
1326874.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,VRTX,neutral
1326875.0,Vertex Confirms Wales Offer Accepted For Access To All Licensed Cystic Fibrosis Medicines,2019-11-13 06:30:00-05:00,VRTX,positive
1326876.0,Vertex Issues Press Release Confirming Northern Ireland Offer Accepted By Cystic Fibrosis Medicines,2019-11-12 10:58:00-05:00,VRTX,positive
1326877.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-12 10:11:00-05:00,VRTX,neutral
1326878.0,"SunTrust Robinson Humphrey Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces $235 Price Target",2019-11-12 06:38:00-05:00,VRTX,neutral
1326879.0,Vertex Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.,2019-11-08 11:12:00-05:00,VRTX,positive
1326880.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,VRTX,positive
1326881.0,Vertex Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-11-01 11:08:00-04:00,VRTX,neutral
1326882.0,Stocks That Hit 52-Week Highs On Friday,2019-11-01 10:31:00-04:00,VRTX,neutral
1326883.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2019-11-01 08:05:00-04:00,VRTX,neutral
1326884.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,VRTX,neutral
1326885.0,"Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $247",2019-10-31 09:43:00-04:00,VRTX,negative
1326886.0,"Vertex Pharma Reports EMA Marketing Authorization Application Validation For VX-445, Tezacaftor, Ivacaftor Triple Combo Treatment In Cystic Fibrosis",2019-10-31 08:58:00-04:00,VRTX,neutral
1326887.0,"Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $229",2019-10-31 08:57:00-04:00,VRTX,neutral
1326888.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,VRTX,positive
1326889.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $250",2019-10-31 07:46:00-04:00,VRTX,negative
1326890.0,Vertex Pharmaceuticals Reaffirms FY19 Product Revenues Guidance $3.70B-$3.75B,2019-10-30 16:14:00-04:00,VRTX,neutral
1326891.0,"Vertex Pharmaceuticals Q3 EPS $1.23 Beats $1.13 Estimate, Sales $950M Beat $948.76M Estimate",2019-10-30 16:12:00-04:00,VRTX,neutral
1326892.0,Stocks That Hit 52-Week Highs On Wednesday,2019-10-30 10:35:00-04:00,VRTX,neutral
1326893.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,VRTX,negative
1326894.0,"Earnings Scheduled For October 30, 2019",2019-10-30 03:39:00-04:00,VRTX,neutral
1326895.0,12 Stocks With The Highest Returns On Assets,2019-10-29 13:00:00-04:00,VRTX,positive
1326896.0,BTIG: Crispr Could Be A Takeover Target For Vertex,2019-10-28 14:58:00-04:00,VRTX,neutral
1326897.0,CRISPR Shares Relatively Quiet As Traders Circulate Earlier Note From BTIG Suggesting 'Vertex's decision to exercise its options to in-license 3 added targets...could fuel speculation CRISPR will end up as Vertex takeover target.',2019-10-28 10:19:00-04:00,VRTX,positive
1326898.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,VRTX,neutral
1326899.0,Vertex Pharma Reports Deal With NHS England For Access To All Licensed Cystic Fibrosis Medicines,2019-10-24 07:29:00-04:00,VRTX,neutral
1326900.0,Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines,2019-10-24 06:13:00-04:00,VRTX,positive
1326901.0,Vertex Shares Are Rallying: What You Need To Know,2019-10-22 10:56:00-04:00,VRTX,positive
1326902.0,14 Stocks With The Highest Long-Term Projected Earnings Growth Rates,2019-10-22 10:15:00-04:00,VRTX,positive
1326903.0,Vertex Pharmaceuticals shares are trading higher after Citigroup analysts maintained a Buy rating on the stock and raised the price target from $205 to $225.,2019-10-22 09:55:00-04:00,VRTX,positive
1326904.0,"Citigroup Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $225",2019-10-22 07:36:00-04:00,VRTX,neutral
1326905.0,"Vertex Shares Resume Trade, Up 0.6%",2019-10-21 16:21:00-04:00,VRTX,positive
1326906.0,Vertex Pharma Shares To Resume Trade At 4:20 p.m. EDT,2019-10-21 16:07:00-04:00,VRTX,positive
1326907.0,Vertex 8-K Shows Raised FY19 CF Net Product Sales From $3.6B-$3.7B To $3.7B-$3.75B,2019-10-21 16:05:00-04:00,VRTX,neutral
1326908.0,Vertex Issues Press Release Confirming FDA Approval Of TRIKAFTA,2019-10-21 15:55:00-04:00,VRTX,positive
1326909.0,Vertex Pharmaceuticals shares are trading higher after the FDA approved Trikafta for cystic fibrosis treatment.,2019-10-21 15:45:00-04:00,VRTX,positive
1326910.0,"Vertex Pharmaceuticals Shares Halted, News Pending",2019-10-21 15:00:00-04:00,VRTX,positive
1326911.0,FDA Approves Vertex's Trikafta For Cystic Fibrosis Treatment,2019-10-21 14:52:00-04:00,VRTX,positive
1326912.0,"Vertex Pharma Reports Spanish Gov't. Has Approved Terms For National Reimbursement Of ORKAMBI, SYMKEVI In Combo With KALYDECO For Cystic Fibrosis Patients In Spain",2019-10-21 13:27:00-04:00,VRTX,positive
1326913.0,"Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO for Eligible Patients Ages 12 and Older, and ORKAMBI in Children Ages 2 to 5, With Certain CFTR Mutations in Australia",2019-10-20 10:05:00-04:00,VRTX,positive
1326914.0,Vertex Pharma Reports Positive CHMP Opinion For KAYLDECO to Treat Eligible Infants With Cystic Fibrosis As Early As 6 Months Of Age,2019-10-18 08:37:00-04:00,VRTX,positive
1326915.0,"Bank of America Reinstates Buy on Vertex Pharmaceuticals, Announces $220 Price Target",2019-10-17 07:24:00-04:00,VRTX,neutral
1326916.0,"Vertex and Ribometrix Announces Strategic Collaboration to Develop RNA-Targeted Small Molecule Therapeutics, Vertex to Make a $20M Upfront Payment",2019-09-30 08:03:00-04:00,VRTX,neutral
1326917.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,VRTX,neutral
1326918.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,VRTX,negative
1326919.0,12 Stocks With The Most Earnings Upside Potential,2019-09-11 07:25:00-04:00,VRTX,neutral
1326920.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $240",2019-09-06 09:44:00-04:00,VRTX,negative
1326921.0,Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M,2019-09-03 09:15:00-04:00,VRTX,neutral
1326922.0,"Goldman Sachs Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to $254; Adds To Conviction List",2019-09-03 08:07:00-04:00,VRTX,neutral
1326923.0,Vertex To Acquire Semma Therapeutics For $950M In Cash; Co. Highlights 'Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes',2019-09-03 08:01:00-04:00,VRTX,neutral
1326924.0,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More",2019-08-31 14:37:00-04:00,VRTX,positive
1326925.0,'Vertex sinks on reports of patient deaths tied to cystic fibrosis drug' -STAT,2019-08-28 11:22:00-04:00,VRTX,neutral
1326926.0,Vertex Pharmaceuticals Announces FDA Acceptance Of NDA For VX-445,2019-08-20 08:09:00-04:00,VRTX,positive
1326927.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,VRTX,positive
1326928.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,VRTX,negative
1326929.0,Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-01 11:26:00-04:00,VRTX,positive
1326930.0,"Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $213",2019-08-01 10:09:00-04:00,VRTX,positive
1326931.0,"Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $230",2019-08-01 09:23:00-04:00,VRTX,negative
1326932.0,"Stifel Nicolaus Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $211",2019-08-01 08:51:00-04:00,VRTX,neutral
1326933.0,Needham Downgrades Vertex Pharmaceuticals to Hold,2019-08-01 07:48:00-04:00,VRTX,neutral
1326934.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,VRTX,negative
1326935.0,"Earnings Scheduled For July 31, 2019",2019-07-31 04:03:00-04:00,VRTX,neutral
1326936.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,VRTX,negative
1326937.0,"Vertex Pharma Names Jeffrey Leiden Chair, Reshma Kewalramani CEO",2019-07-25 08:20:00-04:00,VRTX,neutral
1326938.0,"Vertex Submits New Drug Application to the FDA for a Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis",2019-07-22 08:01:00-04:00,VRTX,neutral
1326939.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,VRTX,negative
1326940.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,VRTX,neutral
1326941.0,Vertex Pharmaceuticals Confirms FDA Approval For SYMDEKO,2019-06-21 14:30:00-04:00,VRTX,positive
1326942.0,FDA Grants Vertex Pharmaceuticals Expanded Indication For SYMDEKO Tablets For PEdiatric PAtients With Cystic Fibrosis,2019-06-21 13:30:00-04:00,VRTX,positive
1326943.0,"Vertex Pharmaceuticals shares are trading higher after the company announced it acquired Exonics Therapeutics, expanding into gene therapy; The company also entered a licensing agreement with CRISPR to further help jump-start its gene-therapy business.",2019-06-07 15:14:00-04:00,VRTX,positive
1326944.0,"Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion",2019-06-07 09:54:00-04:00,VRTX,positive
1326945.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,VRTX,positive
1326946.0,"Vertex And CRISPR Therapeutics Enter Licensing Agreement To Discover And Develop Gene Therapies For DMD And DM1; Vertex To Acquire Exonics For $245M Plus Potential Milestones, CRISPR To Receive Upfront Payment Of $175M",2019-06-06 17:15:00-04:00,VRTX,positive
1326947.0,"Vertex Pharma Reports Selected Triple Combo Of Next-Gen Corrector VX-445, Tezacaftor, Ivacaftor To Submit For Potential Global Regulatory Approvals For Peoples Ages 12+ With Cystic Fibrosis",2019-05-30 08:01:00-04:00,VRTX,neutral
1326948.0,"Goldman Sachs Assumes Vertex Pharmaceuticals Incorporated - Common Stock at Buy, Announces Price Target $220",2019-05-23 09:05:00-04:00,VRTX,neutral
1326949.0,"Benzinga's Top Upgrades, Downgrades For May 21, 2019",2019-05-21 09:16:00-04:00,VRTX,positive
1326950.0,"Credit Suisse Initiates Coverage On Vertex Pharmaceuticals Incorporated - Common Stock with Outperform Rating, Announces $209 Price Target",2019-05-21 07:09:00-04:00,VRTX,positive
1326951.0,"UPDATE: Vertex Says Kymera To Receive $70M Upfront Payment, Including Equity Investment",2019-05-15 08:37:00-04:00,VRTX,neutral
1326952.0,"Vertex Pharma, Kymera Therapeutics Report Establishment Of Strategic Collaboration To Discover, Develop Targeted Protein Degradation Medicines For Serious Diseases",2019-05-15 08:37:00-04:00,VRTX,negative
1326953.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,VRTX,positive
1326954.0,Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2019-05-01 14:58:00-04:00,VRTX,positive
1326955.0,"Vertex Pharmaceuticals Q1 EPS $1.14 Beats $0.98 Estimate, Sales $857M Beat $850.93M Estimate",2019-04-30 16:12:00-04:00,VRTX,neutral
1326956.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,VRTX,negative
1326957.0,Vertex Pharma Reports FDA Approval Of DALYDECO as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age,2019-04-30 08:37:00-04:00,VRTX,positive
1326958.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,VRTX,positive
1326959.0,"Earnings Scheduled For April 30, 2019",2019-04-30 06:18:00-04:00,VRTX,neutral
1326960.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-04-27 11:44:00-04:00,VRTX,neutral
1326961.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,VRTX,positive
1326962.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,VRTX,positive
1326963.0,CRISPR Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For The Treatment Of Beta Thalassemia,2019-04-16 07:01:00-04:00,VRTX,neutral
1326964.0,Evercore ISI Group Initiates Coverage On Vertex Pharmaceuticals with In-Line Rating,2019-04-12 07:37:00-04:00,VRTX,neutral
1326965.0,Get In On Genomics With This New ETF,2019-04-10 08:01:00-04:00,VRTX,neutral
1326966.0,Vertex Pharma Names Charlie Wagner CFO,2019-04-02 08:08:00-04:00,VRTX,neutral
1326967.0,"Benzinga's Top Upgrades, Downgrades For March 26, 2019",2019-03-26 09:18:00-04:00,VRTX,positive
1326968.0,William Blair Upgrades Vertex Pharmaceuticals to Outperform,2019-03-26 07:22:00-04:00,VRTX,neutral
1326969.0,"Benzinga's Top Upgrades, Downgrades For March 19, 2019",2019-03-19 09:19:00-04:00,VRTX,positive
1326970.0,SVB Leerink Downgrades Vertex Pharmaceuticals to Market Perform,2019-03-19 07:07:00-04:00,VRTX,neutral
1326971.0,Vertex Pharmaceuticals Earlier Announced TGA Approval For SYMDEKO In  Cystic Fibrosis,2019-03-12 06:16:00-04:00,VRTX,positive
1326972.0,7 Biggest Price Target Changes For Thursday,2019-03-07 09:57:00-05:00,VRTX,neutral
1326973.0,"Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $230",2019-03-07 08:57:00-05:00,VRTX,neutral
1326974.0,"Vertex Reports Treatment With Triple Combo VX-445, Tezacaftor, Ivacaftor Resulted In Statistically Significant Improvements In Lung Function In 2 Phase 3 Studies For Cystic Fibrosis",2019-03-06 08:11:00-05:00,VRTX,positive
1326975.0,Markets React Amid Report FDA Commish Scott Gottlieb Will Resign,2019-03-05 15:39:00-05:00,VRTX,negative
1326976.0,CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Enrolled In A Phase 1/2 Clinical Study Of Ctx001 In Severe Scd In The U.S. And Is Expected To Be Infused With Ctx001 In Mid-2019,2019-02-25 08:13:00-05:00,VRTX,negative
1326977.0,CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Treated With Ctx001 In A Phase 1/2 Clinical Study Of Patients With Transfusion-Dependent Beta Thalassemia,2019-02-25 08:12:00-05:00,VRTX,neutral
1326978.0,"Vertex Reports Results From Phase 3 Study Of Tezacaftor In Combo With Ivacaftor In Children 6-11 With Cystic Fibrosis In Europe, Australia: Study Met Primary Endpoint",2019-02-14 09:06:00-05:00,VRTX,neutral
1326979.0,"Vertex Pharma Filing Shows Registration For Mixed Securities Offering, No Size Disclosed",2019-02-13 16:48:00-05:00,VRTX,neutral
1326980.0,"Hearing Alliance Bernstein Reduces Stakes In Apple, Facebook, Amazon, Citigroup, Crown Castle; Raises Stakes In Vertex Pharmaceuticals, Procter & Gamble, Regency Centers, Microsoft, Pfizer",2019-02-13 13:14:00-05:00,VRTX,positive
1326981.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,VRTX,neutral
1326982.0,"Vertex Pharmaceuticals Q4 EPS $1.30 Beats $1.06 Estimate, Sales $868M Beat $819.6M Estimate",2019-02-05 16:23:00-05:00,VRTX,neutral
1326983.0,"Earnings Scheduled For February 5, 2019",2019-02-05 04:01:00-05:00,VRTX,neutral
1326984.0,Health Canada Grants  Vertex Pharmaceuticals Market Authorization For KALYDECO In Children Ages 12 To <24 Months With Certain Mutations In The CTFR Gene,2019-01-28 09:18:00-05:00,VRTX,positive
1326985.0,"Vertex Pharma Reports Its Interim CFO, Ian Smith, To Leave Co., Cites 'personal behavior that violated Vertex's Code of Conduct and values and is unrelated to the Company's financial and business performance'",2019-01-23 16:38:00-05:00,VRTX,negative
1326986.0,Vertex Pharmaceuticals On Monday Announced European Commission Approval Of ORKAMBI For Treatment Of Children With Cystic Fibrosis Aged 2 to 5 Years Old,2019-01-22 09:23:00-05:00,VRTX,positive
1326987.0,Vertex Pharmaceuticals Option Alert: Fri $185 Calls at the Ask: 500 @ $2.0 vs 8524 OI; Earnings 1/30 After Close [est] Ref=$185.932,2019-01-16 15:37:00-05:00,VRTX,positive
1326988.0,"Citigroup Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $205",2019-01-04 10:35:00-05:00,VRTX,negative
1326989.0,"CRISPR Therapeutics, Vertex Report FDA Fast Track Designation For CTX001 For Treatment Of Sickle Cell Disease",2019-01-04 07:07:00-05:00,VRTX,neutral
1326990.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2019",2019-01-02 09:15:00-05:00,VRTX,positive
1326991.0,Raymond James Downgrades Vertex Pharmaceuticals to Market Perform,2019-01-02 07:37:00-05:00,VRTX,neutral
1326992.0,"Crispr Therapeutics 10%+ Owner Vertex Pharmaceuticals Buys 90,742 @ Avg Price: $24.08",2018-12-26 16:50:00-05:00,VRTX,neutral
1326993.0,6 Valuable Pipeline Drugs With Upcoming Catalysts,2018-12-26 14:22:00-05:00,VRTX,positive
1326994.0,HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity,2018-12-26 11:50:00-05:00,VRTX,positive
1326995.0,"Vertex Pharma Reports Will Submit ORKAMBI, SYMKEVI To Be Used In Combo With Ivacaftor To Scottish Medicines Consortium For Appraisal",2018-12-19 12:05:00-05:00,VRTX,neutral
1326996.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $210",2018-12-19 07:53:00-05:00,VRTX,negative
1326997.0,Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved,2018-12-18 08:55:00-05:00,VRTX,positive
1326998.0,Vertex Reports Positive Phase 2 Third Proof-Of-Concept Study With NaV1.8 Inhibitor VX-150 Met Its Primary Endpoint,2018-12-18 08:32:00-05:00,VRTX,positive
1326999.0,Guggenheim Reinstates Neutral on Vertex Pharmaceuticals,2018-12-18 08:00:00-05:00,VRTX,neutral
1327000.0,Vertex Pharmaceuticals CFO Tom Graney Leaving Co. For Generation Bio,2018-12-17 10:04:00-05:00,VRTX,neutral
1327001.0,Vertex Pharma Reports Health Canada Granted Market Authorization For ORKAMBI For Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease,2018-12-13 08:00:00-05:00,VRTX,positive
1327002.0,5 Biotech Companies To Keep On Your M&A Watchlist For 2019,2018-12-10 12:32:00-05:00,VRTX,neutral
1327003.0,Vertex Announces EC Approval for KALYDECO to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene,2018-11-29 03:47:00-05:00,VRTX,positive
1327004.0,Vertex Pharmaceuticals shares are trading up 5.0% after the company reported two Phase 3 studies met primary endpoints.,2018-11-27 13:23:00-05:00,VRTX,positive
1327005.0,"Vertex Pharma Reports 2 Phase 3 Studies Of Triple Combo Of VX-659, Tezacaftor, Ivacaftor Met Primary Endpoint",2018-11-27 08:03:00-05:00,VRTX,neutral
1327006.0,Vertex Receives European CHMP Positive Opinion For ORKAMBI For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease,2018-11-16 08:02:00-05:00,VRTX,positive
1327007.0,Vertex Announces EC for Third Cystic Fibrosis Medicine SYMKEVI to be Used in Combination with Ivacaftor for People with CF Aged 12 and Older with Certain Mutations in the CFTR Gene,2018-11-01 04:17:00-04:00,VRTX,positive
1327008.0,"Benzinga's Top Upgrades, Downgrades For October 26, 2018",2018-10-26 09:22:00-04:00,VRTX,positive
1327009.0,"H.C. Wainwright Upgrades Vertex Pharmaceuticals to Buy, Raises Price Target to $220",2018-10-26 07:22:00-04:00,VRTX,neutral
1327010.0,"Raymond James Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $201",2018-10-25 11:25:00-04:00,VRTX,negative
1327011.0,"BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $192",2018-10-25 10:34:00-04:00,VRTX,negative
1327012.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,VRTX,negative
1327013.0,Vertex Sees FY18 CF Product Sales $2.9B-$3B,2018-10-24 16:03:00-04:00,VRTX,neutral
1327014.0,"Vertex Pharmaceuticals Incorporated Q3 Adj. EPS $1.09 Beats $1.01 Estimate, Sales $784.535M Miss $787.32M Estimate",2018-10-24 16:02:00-04:00,VRTX,negative
1327015.0,Vertex Pharmaceuticals Q3 Earnings Outlook,2018-10-24 08:22:00-04:00,VRTX,neutral
1327016.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,VRTX,positive
1327017.0,"Earnings Scheduled For October 24, 2018",2018-10-24 04:05:00-04:00,VRTX,neutral
1327018.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,VRTX,neutral
1327019.0,Vertex Receives European CHMP Positive Opinion For KALYDECO To Treat Patients With Cystic Fibrosis Aged 12 to <24 Months With Certain Mutations In The CFTR Gene,2018-10-19 07:54:00-04:00,VRTX,positive
1327020.0,Vertex Data To Be Presented At North American Cystic Fibrosis Conference (NACFC) October 18-20,2018-10-18 11:47:00-04:00,VRTX,neutral
1327021.0,"Hearing Morgan Stanley Out Defending Vertex After Potential Competitor, Proteostasis, Released Phl Data; Firm Says Would 'Caution' Over-Interpretation Of Proteostasis Data As It Only Includes ~5 Patient Arm, Sweat Chloride Reduction Was 'Modest",2018-10-18 11:11:00-04:00,VRTX,neutral
1327022.0,Surverying The Q3 Earnings Heat Map,2018-10-16 13:30:00-04:00,VRTX,neutral
1327023.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,VRTX,positive
1327024.0,CRISPR Therapeutics and Vertex Announce FDA Lifted Clinical Hold on CTX001,2018-10-10 16:01:00-04:00,VRTX,neutral
1327025.0,Vertex Pharma Shares Appear Unaffected Over Last Few Mins As Traders Circulate Canadian Officials Recommending Co.'s Drug Should Not Be Eligible For Reimburement,2018-10-05 13:41:00-04:00,VRTX,positive
1327026.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,VRTX,neutral
1327027.0,"Cantor Fitzgerald Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces $217 Price Target",2018-10-01 08:20:00-04:00,VRTX,negative
1327028.0,Vertex Announces Access Contract In Denmark For Current And Future Cystic Fibrosis Medicines,2018-10-01 08:13:00-04:00,VRTX,neutral
1327029.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,VRTX,positive
1327030.0,"Stocks That Made New 52-Week Highs So Far Today Include: TJX Companies, HCA Healthcare , Vertex Pharma, F5 Networks, Amgen, Tractor Supply, Visa, Illumina, Cooper Companies, CF Industries, Activision Blizzard, Salesforce, and Aon",2018-09-27 13:36:00-04:00,VRTX,neutral
1327031.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,VRTX,neutral
1327032.0,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron",2018-09-27 08:20:00-04:00,VRTX,neutral
1327033.0,"Stocks That Made New 52-Week Highs So Far Today Include: Becton Dickinson, PerkinElmer, TJX Companies, Medtronic, Danaher, Mastercard, Visa, Illumina, Motorola Solutions, Salesforce, Ross Stores, Edward Lifesciences, and Boston Scientific",2018-09-26 12:58:00-04:00,VRTX,positive
1327034.0,'$VRTX Phase 3 data readouts for  triple regimen (cystic fibrosis) in late 2018. Enrollment just completed. Pretty much as expected (hoped for.)'-STAT's Adam Feuerstein Tweets,2018-09-06 08:10:00-04:00,VRTX,positive
1327035.0,"Vertex Reports Completion Of Enrollment Of 2 Phase 3 Studies Of VX-659 In Triple Combo With Tezacaftor, Ivacaftor For Treatment Of Cystic Fibrosis",2018-09-06 08:04:00-04:00,VRTX,neutral
1327036.0,Vertex Pharmaceuticals On Monday Announced Reimbursement Agreement In Australia For ORKAMBI In Cystic Fibrosis,2018-09-04 08:50:00-04:00,VRTX,positive
1327037.0,'First company-sponsored trial of CRISPR in patients launches' -STAT News,2018-08-31 11:25:00-04:00,VRTX,neutral
1327038.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,VRTX,neutral
1327039.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,VRTX,neutral
1327040.0,"Stocks That Made New 52-Week Highs So Far Today Include: Salesforce, Textron, TJX, Kansas City Southern, Dover, HCA, United Continental, Ingersoll-Rand, Xilinx, Thermo Fisher, Progressive, Microsoft, Apple, Paypal, Cisco, UnitedHealth, Visa & Mastercard",2018-08-29 13:57:00-04:00,VRTX,positive
1327041.0,Vertex Receives Positive PBAC Recommendation for Reimbursement of ORKAMBI to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation,2018-08-20 03:45:00-04:00,VRTX,positive
1327042.0,Vertex Pharmaceuticals Announces FDA Approval Of KALYDECO As First And Only Medicine To Treat  Underlying Cause Of CF In Children Ages 12 to <24 Months With Certain Mutations In CFTR Gene,2018-08-15 15:30:00-04:00,VRTX,positive
1327043.0,Vertex Pharma Has fda PDUFA Date Today for ORKAMBI in Kids 12 to Under 2 Years of Age; BZ NOTE: Co. Received Approval For ORKAMBI in 2-5 Year Olds August 7th,2018-08-15 09:25:00-04:00,VRTX,positive
1327044.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,VRTX,negative
1327045.0,"The Week Ahead: Nvidia, Retailer Earnings In Focus",2018-08-13 13:26:00-04:00,VRTX,neutral
1327046.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-08-12 16:52:00-04:00,VRTX,neutral
1327047.0,Vertex Pharma Reports FDA Approved ORKAMBI For Treatment Of Underlying Cause Of Cystic Fibrosis For Children Ages 2-5 Years With Most Common Form Of Disease,2018-08-07 16:00:00-04:00,VRTX,positive
1327048.0,Stifel Transfers Coverage Of Vertex Pharmaceuticals With A Buy And $200 Price Target,2018-08-07 08:23:00-04:00,VRTX,neutral
1327049.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,VRTX,negative
1327050.0,REMINDER: Vertex Pharma Has FDA PDUFA Date Today for Ivacaftor for Cystic Fibrosis,2018-08-07 06:28:00-04:00,VRTX,neutral
1327051.0,"The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal",2018-08-06 15:30:00-04:00,VRTX,neutral
1327052.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs",2018-08-05 09:44:00-04:00,VRTX,neutral
1327053.0,"Citigroup Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $206",2018-07-30 08:32:00-04:00,VRTX,neutral
1327054.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,VRTX,neutral
1327055.0,European Union Medicines Agency Has Recommended Approval For Vertex Pharma's Tezacaftor/Ivacaft Cystic Fibrosis Combo Treatment,2018-07-27 08:20:00-04:00,VRTX,positive
1327056.0,"UBS Maintains Neutral on Vertex Pharmaceuticals, Raises Price Target to $188",2018-07-26 09:00:00-04:00,VRTX,neutral
1327057.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,VRTX,negative
1327058.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $211",2018-07-26 08:25:00-04:00,VRTX,negative
1327059.0,Vertex Pharmaceuticals Raises FY18 Cystic Fibrosis Product Sales Outlook From $2.65B-$2.80B To $2.9B-$3B,2018-07-25 16:06:00-04:00,VRTX,neutral
1327060.0,"Vertex Pharmaceuticals Q2 Adj. EPS $0.94 Beats $0.75 Estimate, Sales $751.22M Beat $682.24M Estimate",2018-07-25 16:03:00-04:00,VRTX,neutral
1327061.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,VRTX,positive
1327062.0,Earnings Preview For Vertex Pharmaceuticals,2018-07-25 08:27:00-04:00,VRTX,neutral
1327063.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,VRTX,neutral
1327064.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,VRTX,positive
1327065.0,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF",2018-07-17 13:30:00-04:00,VRTX,positive
1327066.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,VRTX,neutral
1327067.0,44 Biggest Movers From Friday,2018-07-02 04:48:00-04:00,VRTX,neutral
1327068.0,35 Stocks Moving In Friday's Mid-Day Session,2018-06-29 12:18:00-04:00,VRTX,neutral
1327069.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,VRTX,positive
1327070.0,24 Stocks Moving In Friday's Pre-Market Session,2018-06-29 08:04:00-04:00,VRTX,neutral
1327071.0,Health Canada Approves Vertex's PrSYMDEKO,2018-06-28 11:19:00-04:00,VRTX,positive
1327072.0,Vertex Reports Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI,2018-06-18 07:04:00-04:00,VRTX,positive
1327073.0,Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of Cystic Fibrosis,2018-06-07 08:43:00-04:00,VRTX,neutral
1327074.0,Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF,2018-06-07 05:51:00-04:00,VRTX,neutral
1327075.0,3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate,2018-05-31 11:45:00-04:00,VRTX,neutral
1327076.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,VRTX,positive
1327077.0,CRISPR and Vertex Pharma Announce FDA Has Placed A Clinical Hold on IND For CTX001 Pending Resolution Of 'Certain Questions' As Part of Its Review,2018-05-30 16:32:00-04:00,VRTX,positive
1327078.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $207.00",2018-04-27 10:28:00-04:00,VRTX,negative
1327079.0,"Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences",2018-04-27 07:25:00-04:00,VRTX,neutral
1327080.0,Vertex Pharma Sees FY18 Sales $2.65B-$2.8B vs $2.78B Est.,2018-04-26 17:04:00-04:00,VRTX,neutral
1327081.0,"Vertex Pharma Q1 Adj. EPS $0.76 Beats $0.62 Est., Sales $638M Beats $617.59M Est.",2018-04-26 17:03:00-04:00,VRTX,neutral
1327082.0,"Vertex Initiates Phase 3 Studies Of VX-445, Tezacaftor And Ivacaftor As A Triple Combination Regimen For Cystic Fibrosis",2018-04-26 16:21:00-04:00,VRTX,neutral
1327083.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,VRTX,neutral
1327084.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,VRTX,neutral
1327085.0,"Vertex Pharma, Q-State Biosciences Report Strategic Collab To Discover Drugs Using Q-State's Novel Optopatch Platform",2018-04-04 08:01:00-04:00,VRTX,positive
1327086.0,Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud',2018-03-20 14:53:00-04:00,VRTX,negative
1327087.0,Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock,2018-03-16 10:59:00-04:00,VRTX,positive
1327088.0,"Vertex Pharma Reports Initiation Of Phase 3 Study Of VX-659, Tezacaftor, Ivacaftor As Triple Combo Regimen For People With CF Who Have 2 Copies Of F508del Mutation",2018-03-01 07:37:00-05:00,VRTX,neutral
1327089.0,46 Biggest Movers From Yesterday,2018-02-26 05:08:00-05:00,VRTX,neutral
1327090.0,Adam Feuerstein  Tweet: I spoke w/ $VRTX. They will report ph3 top-line results AFTER 12 week safety is collected. (Not at 4 week efficacy.) They will also file once 12-week safety is collected. No timeline yet on when we could see top-line r,2018-02-21 16:25:00-05:00,VRTX,positive
1327091.0,Vertex Initiates Phase 3 VX-659 Study,2018-02-21 16:05:00-05:00,VRTX,neutral
1327092.0,"Vertex Phase 2 Study Of VX-150 Met Primary Endpoint Of Statistically Significant Improvement In SPID24 With VX-150 vs Placebo, Advances VX-128 Into Clinical Development",2018-02-14 08:34:00-05:00,VRTX,positive
1327093.0,"JMP Securities Maintains Market Outperform on Vertex Pharmaceuticals, Raises price target to $211.00",2018-02-13 10:34:00-05:00,VRTX,positive
1327094.0,"Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Raises price target to $196.00",2018-02-13 07:58:00-05:00,VRTX,positive
1327095.0,Vertex Announces FDA Approved SYMDEKO,2018-02-12 16:51:00-05:00,VRTX,positive
1327096.0,"Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $200.00",2018-02-02 09:37:00-05:00,VRTX,negative
1327097.0,"Bank of America Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $197.00",2018-02-01 12:23:00-05:00,VRTX,neutral
1327098.0,"BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $191.00",2018-02-01 10:29:00-05:00,VRTX,neutral
1327099.0,"Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $200.00",2018-02-01 08:41:00-05:00,VRTX,negative
1327100.0,31 Stocks Moving In Thursday's Pre-Market Session,2018-02-01 08:01:00-05:00,VRTX,neutral
1327101.0,"Vertex Reports Q4 Adj. EPS $0.61 vs $0.53 Est., Sales $651.634M vs $594.7M Est.",2018-01-31 16:35:00-05:00,VRTX,neutral
1327102.0,"Vertex Reports Selected 2 Next-Gen Correctors, VX-659, VX-445 To Advance Into Phase 3 Development",2018-01-31 16:04:00-05:00,VRTX,neutral
1327103.0,Attention Biotech Investors: February PDUFA Catalysts Come Calling,2018-01-31 15:30:00-05:00,VRTX,neutral
1327104.0,Earnings Preview For Vertex Pharmaceuticals,2018-01-31 13:35:00-05:00,VRTX,neutral
1327105.0,"Earnings Scheduled For January 31, 2018",2018-01-31 04:22:00-05:00,VRTX,neutral
1327106.0,AbbVie Shares Double In A Year; Leerink Moves To Sidelines,2018-01-29 15:51:00-05:00,VRTX,positive
1327107.0,"BofA Adds Allergan, Vertex Pharma To 'US 1' List",2018-01-23 07:58:00-05:00,VRTX,neutral
1327108.0,Vertex's Cystic Fibrosis Drug Given The Okay For Pediatric Use In Europe,2018-01-11 12:11:00-05:00,VRTX,positive
1327109.0,Vertex Announces EU Approval for ORKAMBI in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation,2018-01-10 04:16:00-05:00,VRTX,positive
1327110.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,VRTX,neutral
1327111.0,"Adam Feuerstein Tweets: $VRTX breakout, on triple combo CF:

Want to take 2 programs into ph3, start 1H '18.

Trial design not finalized but believe shorter endpoints 4 weeks or 8-12 weeks will be allowed. 

#JPM18",2018-01-08 13:17:00-05:00,VRTX,neutral
1327112.0,Vertex Pharma's Earnings Preview,2018-01-08 11:55:00-05:00,VRTX,neutral
1327113.0,"5 Stocks To Watch For January 8, 2018",2018-01-08 05:57:00-05:00,VRTX,neutral
1327114.0,"Earnings Scheduled For January 8, 2018",2018-01-08 05:48:00-05:00,VRTX,neutral
1327115.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,VRTX,positive
1327116.0,Bank of America Upgrades Vertex Pharmaceuticals to Buy,2018-01-05 08:32:00-05:00,VRTX,neutral
1327117.0,10 Best Stocks Of 2017,2017-12-31 11:34:00-05:00,VRTX,positive
1327118.0,"Benzinga's Bulls & Bears: Looking Back, Looking Forward",2017-12-24 09:05:00-05:00,VRTX,neutral
1327119.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,VRTX,neutral
1327120.0,"Deutsche Bank Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces $175.00 Price Target",2017-12-13 08:41:00-05:00,VRTX,neutral
1327121.0,"Vertex Pharma, CRISPR Therapeutics Report Will Co-Develop, Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell, B-Thalassemia",2017-12-12 08:31:00-05:00,VRTX,neutral
1327122.0,Vertex Reports Phase 3 Study Of KALYDECO Met Primary Endpoint And Showed Improvements Across Multiple Endpoints,2017-12-07 08:09:00-05:00,VRTX,positive
1327123.0,Vertex Receives CHMP Positive Opinion for ORKAMBI for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union,2017-11-10 07:30:00-05:00,VRTX,positive
1327124.0,Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market,2017-11-08 17:10:00-05:00,VRTX,positive
1327125.0,"Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead",2017-11-07 09:06:00-05:00,VRTX,positive
1327126.0,"UPDATE: Vertex Highlights 'FDA Priority Review action date of February 28, 2018'",2017-11-03 10:36:00-04:00,VRTX,neutral
1327127.0,UPDATE: Vertex Says Data On Tezacaftor/Ivacaftor Combo 'showed significant improvements in lung function (ppFEV1) with a favorable safety profile across multiple patient groups',2017-11-03 10:35:00-04:00,VRTX,positive
1327128.0,Vertex Pharma Reports Phase 3 Studies Of Tezacaftor/Ivacaftor Combo Treatment In People With CF Ages 12+ Will Be Published In NEJM,2017-11-03 10:35:00-04:00,VRTX,neutral
1327129.0,"Vertex Q3 Adj. EPS $0.53 vs $0.31 Est., Sales $578.17M vs $520.13M Est.",2017-10-25 16:35:00-04:00,VRTX,neutral
1327130.0,"Earnings Scheduled For October 25, 2017",2017-10-25 04:24:00-04:00,VRTX,neutral
1327131.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,VRTX,positive
1327132.0,"Benzinga's Bulls And Bears Of The Past Week: Netflix, Intel, Tesla And More",2017-10-02 10:29:00-04:00,VRTX,neutral
1327133.0,"Benzinga's Top Upgrades, Downgrades For September 29, 2017",2017-09-29 10:48:00-04:00,VRTX,positive
1327134.0,3 Reasons To Like Vertex Pharma Shares,2017-09-29 08:56:00-04:00,VRTX,positive
1327135.0,"DA Davidson Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces $200.00 Price Target",2017-09-29 06:14:00-04:00,VRTX,neutral
1327136.0,"When Bull Markets Die: What To Watch For, What Stocks Could Be The First To Get Hit",2017-09-25 12:26:00-04:00,VRTX,negative
1327137.0,Vertex's Rocky September Causes Vetr To Urge Sell,2017-09-21 08:13:00-04:00,VRTX,neutral
1327138.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,VRTX,neutral
1327139.0,STAT News' Adam Feuerstein Tweets '$VRTX shuts down study of long-acting Kalydeco but insists development still on track',2017-09-11 14:40:00-04:00,VRTX,neutral
1327140.0,STAT News Publishes 'Vertex shuts down study of long-acting Kalydeco but insists development still on track',2017-09-11 14:39:00-04:00,VRTX,neutral
1327141.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,VRTX,neutral
1327142.0,Vertex Pharmaceuticals Names Tom Graney SVP and CFO,2017-09-06 08:14:00-04:00,VRTX,neutral
1327143.0,"Vertex Reports Acceptance Of Applications For Review Of Tezacaftor/Ivacaftor Combo Treatment Of Cystic Fibrosis By FDA, EMA",2017-08-24 11:30:00-04:00,VRTX,positive
1327144.0,13G/A Filing Shows T. Rowe Price Reporting 10.6% Stake In Vertex Pharmaceuticals,2017-08-10 14:57:00-04:00,VRTX,neutral
1327145.0,Vertex Announces That The FDA Approves KALYDECO,2017-08-01 08:09:00-04:00,VRTX,positive
1327146.0,UPDATE: Vertex Raises FY17 KALYDECO Product Sales Outlook To $770M-$800M; Sees ORKAMBI Sales $1.1B-$1.3B; Total CF Product Sales Guidance $1.87B-$2.1B,2017-08-01 08:04:00-04:00,VRTX,neutral
1327147.0,Vertex Raises FY17 KALYDECO Product Sales,2017-08-01 08:03:00-04:00,VRTX,neutral
1327148.0,Vertex Pharma Reports FDA Approval Of KALYDECO For CF With Certain Residual Function Mutations,2017-08-01 08:03:00-04:00,VRTX,positive
1327149.0,From Vertex Q2 Earnings Conference Call: Mgmt. Is Interested In Buying Early-Stage Assets In Disease Areas Consistent With CF,2017-07-26 17:44:00-04:00,VRTX,positive
1327150.0,"Vertex Pharmaceuticals Incorporated Reports Q2 Adj. EPS $0.39 vs $0.35 Est., Sales $544.135M vs $487.49M Est.",2017-07-26 16:02:00-04:00,VRTX,neutral
1327151.0,Concert Pharma Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex,2017-07-24 07:02:00-04:00,VRTX,positive
1327152.0,Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide,2017-07-19 14:30:00-04:00,VRTX,positive
1327153.0,18 Biggest Mid-Day Gainers For Wednesday,2017-07-19 12:22:00-04:00,VRTX,neutral
1327154.0,Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet,2017-07-19 12:04:00-04:00,VRTX,negative
1327155.0,A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals,2017-07-19 11:23:00-04:00,VRTX,negative
1327156.0,Hearing UBS Downgrades Vertex In Mid-Day Note,2017-07-19 10:48:00-04:00,VRTX,neutral
1327157.0,Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates,2017-07-19 10:08:00-04:00,VRTX,neutral
1327158.0,5 Biggest Price Target Changes For Wednesday,2017-07-19 09:57:00-04:00,VRTX,neutral
1327159.0,More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data,2017-07-19 09:45:00-04:00,VRTX,neutral
1327160.0,"Benzinga's Top Upgrades, Downgrades For July 19, 2017",2017-07-19 09:25:00-04:00,VRTX,positive
1327161.0,The Market In 5 Minutes,2017-07-19 08:47:00-04:00,VRTX,neutral
1327162.0,"Vertex Pharmaceuticals Shares Up 27% In Pre-Market Following Strong Phase 1, 2 Data From 3 Different Triple Combo Regimens; String Of Analyst Upgrades",2017-07-19 08:25:00-04:00,VRTX,positive
1327163.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-07-19 08:09:00-04:00,VRTX,neutral
1327164.0,Cowen & Co. Upgrades Vertex Pharmaceuticals to Outperform,2017-07-19 07:32:00-04:00,VRTX,neutral
1327165.0,Raymond James Upgrades Vertex Pharmaceuticals to Outperform,2017-07-19 07:26:00-04:00,VRTX,neutral
1327166.0,Janney Capital Upgrades Vertex Pharmaceuticals to Buy,2017-07-19 06:24:00-04:00,VRTX,neutral
1327167.0,Barclays Upgrades Vertex Pharmaceuticals to Overweight,2017-07-19 06:07:00-04:00,VRTX,negative
1327168.0,STAT News' Adam Feuerstein Tweets 'Do not be surprised to see $VRTX get FDA sign off to accelerate ph3s and secure faster approval for the triples.',2017-07-18 16:18:00-04:00,VRTX,positive
1327169.0,Vertex Pharma Shares To Resume Trade At 4:20 p.m. EDT,2017-07-18 16:04:00-04:00,VRTX,positive
1327170.0,STAT News' Adam Feuerstein Tweets 'New $VRTX drugs show dramatic gains for tough-to-treat cystic fibrosis patients >  https://www.statnews.com/2017/07/18/vertex-cystic-fibrosis-results/   Triple combo data. Huge!',2017-07-18 16:03:00-04:00,VRTX,positive
1327171.0,UPDATE: Vertex Says 'All 3 triple combination regimens were generally well tolerated across the studies',2017-07-18 16:02:00-04:00,VRTX,positive
1327172.0,"UPDATE: Vertex Says 'Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients'",2017-07-18 16:02:00-04:00,VRTX,positive
1327173.0,"Vertex Reports Phase 1, 2 Data From 3 Different Triple Combo Regimens In People With Cystic Fibrosis",2017-07-18 16:01:00-04:00,VRTX,neutral
1327174.0,Vertex Shares Halted News Pending,2017-07-18 16:00:00-04:00,VRTX,positive
1327175.0,"Vertex Announces Reimbursement Agreement in Italy for ORKAMBI, Which Treats the Underlying Cause of CF in People Ages 12 and Older with Two Copies of the F508del Mutation",2017-07-13 04:45:00-04:00,VRTX,positive
1327176.0,"Jefferies Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces $155.00 Price Target",2017-07-11 07:37:00-04:00,VRTX,neutral
1327177.0,The Royalty-Amassing Strategy Of Royalty Pharma,2017-07-10 16:11:00-04:00,VRTX,neutral
1327178.0,2 Stocks Up 50% In 2017 That Have Further Room For Upside,2017-07-07 13:04:00-04:00,VRTX,neutral
1327179.0,How Have The Best And Worst Stocks Of 2016 Performed In 2017?,2017-07-05 14:49:00-04:00,VRTX,neutral
1327180.0,5 Hottest Stocks Of The First Half Of 2017,2017-07-03 12:04:00-04:00,VRTX,neutral
1327181.0,2 Reasons Vertex Pharmaceuticals Just Got Upgraded,2017-06-23 13:25:00-04:00,VRTX,neutral
1327183.0,"Benzinga's Top Upgrades, Downgrades For June 23, 2017",2017-06-23 09:23:00-04:00,VRTX,positive
1327184.0,Needham Upgrades Vertex Pharmaceuticals to Buy,2017-06-23 07:15:00-04:00,VRTX,neutral
1327189.0,Vertex Pharmaceuticals Receives FDA Orphan Designation for Tezacaftor and Ivacaftor Combination Therapy,2017-06-18 21:54:00-04:00,VRTX,neutral
1327191.0,"Vertex Announces Nine Presentations of Data on ORKAMBI, KALYDECO at ECFS Conference",2017-06-09 04:39:00-04:00,VRTX,neutral
1327192.0,"Benzinga's Top Upgrades, Downgrades For June 2, 2017",2017-06-02 09:32:00-04:00,VRTX,positive
1327193.0,Oppenheimer Upgrades Vertex Pharmaceuticals to Outperform,2017-06-02 06:37:00-04:00,VRTX,neutral
1327194.0,"Vertex Announces Long-Term Reimbursement Agreement With Ireland For ORKAMBI, Future Cystic Fibrosis Medicines",2017-06-01 13:18:00-04:00,VRTX,positive
1327195.0,Concert Pharma Reports Shareholder Approval of CTP-656 Asset Purchase Deal with Vertex,2017-05-24 10:02:00-04:00,VRTX,positive
1327196.0,FDA Approves Vertex Pharma's KALYDECO,2017-05-17 16:09:00-04:00,VRTX,positive
1327197.0,"X-Chem, Vertex Enter into Multi-Target Genetic Disease Collaboration",2017-05-16 08:18:00-04:00,VRTX,neutral
1327198.0,"Vertex Reaffirms FY17 Outlook for ORKAMBI, KALYDECO",2017-04-27 18:26:00-04:00,VRTX,neutral
1327199.0,Vertex Reports Q1 Adj. EPS $0.41 vs $0.40 Est.,2017-04-27 18:26:00-04:00,VRTX,neutral
1327200.0,"Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More",2017-04-17 08:21:00-04:00,VRTX,neutral
1327201.0,Hearing Fresenius Said to Consider Offer for Akorn,2017-04-07 13:06:00-04:00,VRTX,neutral
1327202.0,"Endo Int'l Shares Spike Into Positive Territory, Now Up 2%, Vertex Shares Also at Session Highs Up 2.3%",2017-04-07 13:05:00-04:00,VRTX,positive
1327203.0,Stocks To Watch In Market Weakness,2017-04-06 13:49:00-04:00,VRTX,negative
1327204.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,VRTX,negative
1327205.0,Benzinga's Option Alert Recap From April 4,2017-04-04 16:46:00-04:00,VRTX,positive
1327206.0,Option Alert: Vertex Apr 110 Calls Sweep: 500 @  ASK  $4.796: 779 traded vs 1909 OI:  Earnings 4/26 After Close (est)  $112.48 Re,2017-04-04 15:33:00-04:00,VRTX,positive
1327207.0,Vetr Turns Bearish On Vertex After Drug Trial Success,2017-03-30 17:04:00-04:00,VRTX,positive
1327208.0,Corbus Pharma's Positive Phase 2 Study: Safety First,2017-03-30 14:56:00-04:00,VRTX,positive
1327209.0,Mid-Afternoon Market Update: RH Gains After Strong Q4 Results; Quorum Health Shares Plummet,2017-03-29 14:32:00-04:00,VRTX,positive
1327210.0,18 Biggest Mid-Day Gainers For Wednesday,2017-03-29 12:46:00-04:00,VRTX,neutral
1327211.0,Mid-Day Market Update: Crude Oil Up 1.5%; Alliqua Biomedical Shares Slide,2017-03-29 12:13:00-04:00,VRTX,negative
1327212.0,Vertex Pharmaceuticals Leaps After Phase 3 Studies Meet Primary Endpoints,2017-03-29 10:21:00-04:00,VRTX,neutral
1327213.0,"Benzinga's Top Upgrades, Downgrades For March 29, 2017",2017-03-29 09:29:00-04:00,VRTX,positive
1327214.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-03-29 08:39:00-04:00,VRTX,neutral
1327215.0,BMO Capital Upgrades Vertex Pharmaceuticals To Outperform,2017-03-29 07:15:00-04:00,VRTX,neutral
1327216.0,Vertex +17% Premarket @ $105; Co Announced Tuesday 2 Phase 3 Studies of Tezacaftor/Ivacaftor Combo Treatment for CF Met Primary Endpoints,2017-03-29 06:26:00-04:00,VRTX,neutral
1327217.0,Vertex Pharma Resumes; Now $101.02,2017-03-28 18:41:00-04:00,VRTX,neutral
1327218.0,Vertex Pharma Shares to Resume Trade at 6:40 p.m. EDT,2017-03-28 18:24:00-04:00,VRTX,positive
1327219.0,Vertex Release Confirms 2 Phase 3 Studies of Tezacaftor/Ivacaftor Combo Treatment Met Primary Endpoints,2017-03-28 18:21:00-04:00,VRTX,neutral
1327220.0,"Hearing Vertex Has Said Will File for US, Euro Approval of Kalydeco/Tezacaftor Combo in Q3'17",2017-03-28 17:37:00-04:00,VRTX,positive
1327221.0,"UPDATE: Vertex Says Adverse Events, Discontinuations with Kalydeco/Tezacaftor Combo Low, Similar to Placebo",2017-03-28 17:37:00-04:00,VRTX,negative
1327222.0,Hearing Vertex Pharma Has Said CF Combo Therapy Significantly Improved Lung Function in Late Stage Trials; Shares Halted,2017-03-28 17:36:00-04:00,VRTX,positive
1327223.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,VRTX,neutral
1327224.0,"Benzinga's Top Upgrades, Downgrades For March 17, 2017",2017-03-17 09:36:00-04:00,VRTX,positive
1327225.0,JMP Securities Upgrades Vertex Pharmaceuticals To Market Outperform,2017-03-17 06:46:00-04:00,VRTX,positive
1327226.0,Wall Street's M&A Chatter From March 6,2017-03-07 07:10:00-05:00,VRTX,neutral
1327227.0,Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher,2017-03-06 14:33:00-05:00,VRTX,positive
1327228.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,VRTX,neutral
1327229.0,Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher,2017-03-06 12:18:00-05:00,VRTX,positive
1327230.0,Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital,2017-03-06 10:07:00-05:00,VRTX,negative
1327231.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,VRTX,neutral
1327232.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Factory Orders Data,2017-03-06 07:42:00-05:00,VRTX,negative
1327233.0,Vertex to Acquire CTP-656 from Concert Pharmaceuticals For $160M Cash And Potential $90M In Milestones,2017-03-06 07:00:00-05:00,VRTX,neutral
1327234.0,Benzinga's Option Alert Recap From February 24,2017-02-24 16:40:00-05:00,VRTX,positive
1327235.0,Option Alert: Vertex Mar 90.0 Calls: 900 @  ASK  $2.00: 1936 traded vs 1546 OI:  Earnings 4/26 After Close (est)  $85.64 Ref,2017-02-24 14:02:00-05:00,VRTX,positive
1327236.0,The Most Overpaid CEOs In S&P 500 Companies That Largely Underperformed The Market,2017-02-24 09:56:00-05:00,VRTX,neutral
1327237.0,"Vertex Reports Q4 Adj EPS $0.35 vs $0.29 Est, Revenue $454M vs $453.4M Est",2017-01-25 16:01:00-05:00,VRTX,neutral
1327238.0,"Earnings Scheduled For January 25, 2017",2017-01-25 04:42:00-05:00,VRTX,neutral
1327239.0,Watch These 8 Huge Call Purchases In Thursday Trade,2017-01-12 04:10:00-05:00,VRTX,positive
1327240.0,Option Alert: Vertex Feb 95.0 Calls: 1400 @  ASK  $1.80: 1403 traded vs 22 OI:  Earnings 1/25 After Close  $83.00 Ref,2017-01-11 10:02:00-05:00,VRTX,positive
1327241.0,"Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex; Vertex To Receive Upfront Payment $230M",2017-01-11 09:01:00-05:00,VRTX,neutral
1327242.0,Vertex Shares Down 2.58%; Hearing JMP Securities Downgraded Co From Outperform To Market Perform,2017-01-09 11:49:00-05:00,VRTX,positive
1327243.0,"Vertex Pharmaceuticals Reports Preliminary Cystic Fibrosis Product Revenue of $453M for Q4, $1.68B for  FY 2016",2017-01-08 17:31:00-05:00,VRTX,neutral
1327244.0,The Year-End Tax-Selling Strategy,2017-01-02 10:42:00-05:00,VRTX,neutral
1327245.0,Which Wall Street Firm Made The Best Stock Picks Of 2016?,2016-12-30 10:09:00-05:00,VRTX,positive
1327246.0,Should You Be Buying 2016 Market Leaders Or Laggards Heading Into 2017?,2016-12-28 13:55:00-05:00,VRTX,neutral
1327247.0,6 Worst Performing S&P 500 Stocks Of 2016,2016-12-27 10:41:00-05:00,VRTX,negative
1327248.0,Oppenheimer Initiates Coverage On Vertex Pharmaceuticals at Perform,2016-12-15 08:03:00-05:00,VRTX,neutral
1327249.0,"Despite A Downgrade, Vetr Still Bullish On Vertex",2016-12-14 15:16:00-05:00,VRTX,neutral
1327250.0,Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff,2016-12-08 09:53:00-05:00,VRTX,neutral
1327251.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-12-05 06:57:00-05:00,VRTX,neutral
1327252.0,"Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion",2016-11-29 10:39:00-05:00,VRTX,neutral
1327253.0,"The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble",2016-11-29 09:02:00-05:00,VRTX,negative
1327254.0,"Baird Analyst Brian Skorney (In Response to Adam Feuerstein) Tweets: @adamfeuerstein This is after patients have already been on Orkambi, not newly started. Really shouldn't expect any additional improvement.",2016-11-29 07:04:00-05:00,VRTX,positive
1327255.0,"Adam Feuerstein Tweets: In $NVLS study, notice alarmingly mediocre efficacy of Orkambi arm absolute change FEV1 0.97% at 12 wks. $VRTX (caveat, cross trial comps.)",2016-11-29 06:49:00-05:00,VRTX,negative
1327256.0,"Adam Feuerstein @adamfeuerstein Tweet: In $NVLS study, notice alarmingly mediocre efficacy of Orkambi arm absolute change FEV1 0.97% at 12 wks. $VRTX (caveat, cross trial comps.)",2016-11-29 06:49:00-05:00,VRTX,negative
1327257.0,Wall Street's M&A Chatter From November 28,2016-11-29 06:46:00-05:00,VRTX,neutral
1327258.0,Barclays Downgrades Vertex Pharmaceuticals to Equal-Weight,2016-11-29 05:57:00-05:00,VRTX,neutral
1327259.0,Vertex Pharmaceuticals Spokesperson Gives Statement Regarding Betaville M&A Report Involving Roche,2016-11-28 12:03:00-05:00,VRTX,neutral
1327260.0,Vertex Pharma Shares Edge Modestly Higher as Traders Passing Around Betaville Reporting Suggesting Roche Interest,2016-11-28 09:46:00-05:00,VRTX,positive
1327261.0,"Vertex Announces Positive Phase 3 Study of ORKAMBI in Children With Cystic Fibrosis Ages 6-11, Study Met Primary Endpoint With Statistically Significant Improvement In Absolute Change IN Lung Clearance Index",2016-11-07 08:32:00-05:00,VRTX,positive
1327262.0,Benzinga's Top Downgrades,2016-11-01 09:15:00-04:00,VRTX,positive
1327263.0,William Blair Downgrades Vertex Pharmaceuticals Incorporated - Common Stock to Market Perform,2016-11-01 07:50:00-04:00,VRTX,neutral
1327264.0,"Vertex Reports Long-Term Data Showing ORKAMBI, KALYDECO Show Potential to Modify Progression of CF",2016-10-27 08:54:00-04:00,VRTX,neutral
1327265.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-10-26 08:25:00-04:00,VRTX,neutral
1327266.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-26 07:02:00-04:00,VRTX,neutral
1327267.0,Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis,2016-10-25 16:24:00-04:00,VRTX,positive
1327268.0,"Vertex Sees FY16 Rev. For ORKAMBI $950-$990M, KALYDECO Rev. Of $685-$705M",2016-10-25 16:04:00-04:00,VRTX,neutral
1327269.0,"Vertex Reports Q3 EPS $0.16 vs. Est. $0.18, Rev. $413.7M vs. Est. $418.3M",2016-10-25 16:04:00-04:00,VRTX,neutral
1327270.0,Goldman Says These 25 Healthcare Stocks Are Immune To The Election,2016-10-24 10:55:00-04:00,VRTX,positive
1327271.0,7 Biggest Price Target Changes For Monday,2016-10-24 09:56:00-04:00,VRTX,neutral
1327272.0,Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright,2016-10-24 09:06:00-04:00,VRTX,neutral
1327273.0,Benzinga's Top Downgrades,2016-10-24 09:05:00-04:00,VRTX,positive
1327274.0,"H.C. Wainwright Downgrades Vertex Pharmaceuticals Incorporated - Common Stock to Neutral, Lowers to $85.00",2016-10-24 07:12:00-04:00,VRTX,negative
1327275.0,"UPDATE: Vertex Says Amended, Expanded Deal Provides Upfront Payment from CFFT of $75M, Development Funding of Up to $6M Annually",2016-10-14 08:22:00-04:00,VRTX,neutral
1327276.0,"8-K from Vertex Pharma Shows Amendment, Expansion of Research, Development, Commercialization Deal with CFFT to Clarify Terms of Relationship",2016-10-14 08:22:00-04:00,VRTX,neutral
1327277.0,"4 After-Hours Movers: Earnings, FDA Trials & Guide-Downs",2016-09-28 17:28:00-04:00,VRTX,neutral
1327278.0,Vertex Shares Falling 4% After Hours To $85/Share,2016-09-28 16:43:00-04:00,VRTX,positive
1327279.0,UPDATE: Vertex Cuts FY16 ORKAMBI Sales Guidance from $1B-$1.1B to $950M-$990M,2016-09-28 16:41:00-04:00,VRTX,negative
1327280.0,Vertex Cuts FY16 ORKAMBI Sales Outlook,2016-09-28 16:40:00-04:00,VRTX,negative
1327281.0,FDA Approves Vertex's Cystic Fibrosis Drug ORKAMBI For Use In Children,2016-09-28 16:40:00-04:00,VRTX,positive
1327282.0,Vertex Pharmaceuticals ORKAMBI Cystic Fibrosis Drug's PDUFA Date Is Sept. 30,2016-09-26 17:21:00-04:00,VRTX,neutral
1327283.0,Technical Alert: Vertex Pharmaceuticals Trying To Find A Bottom,2016-09-14 14:22:00-04:00,VRTX,positive
1327284.0,Hearing Vertex Defended At RBC,2016-09-14 12:29:00-04:00,VRTX,neutral
1327285.0,UPDATE: Vertex Pharma Comments Coming from Exec at Morgan Stanley Global Healthcare Conference,2016-09-14 12:01:00-04:00,VRTX,neutral
1327286.0,Vertex Pharma Shares Tumble Nearly $10 as Hearing Co. Seeing 'Unexpected' Slowing of Prescription Refills During Jul. and Aug.,2016-09-14 12:00:00-04:00,VRTX,positive
1327287.0,"The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A",2016-09-14 09:17:00-04:00,VRTX,positive
1327288.0,Can You Guess This Chart?,2016-09-14 07:29:00-04:00,VRTX,neutral
1327289.0,Benzinga's Top Initiations,2016-09-13 09:22:00-04:00,VRTX,positive
1327290.0,Raymond James Initiates Coverage on Vertex Pharmaceuticals at Market Perform,2016-09-13 04:25:00-04:00,VRTX,neutral
1327291.0,Vertex Says VX-661 and ivacaftor Results Do Not Support Continuation Of The Study,2016-08-15 16:22:00-04:00,VRTX,negative
1327292.0,Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside,2016-08-15 15:14:00-04:00,VRTX,positive
1327293.0,"Vertex Reports Q2 EPS $0.24 vs $0.21 Est, Rev $426M vs $427.94M Est",2016-07-27 17:19:00-04:00,VRTX,neutral
1327294.0,"Earnings Scheduled For July 27, 2016",2016-07-27 04:04:00-04:00,VRTX,neutral
1327295.0,"UPDATE: Moderna Therapeutics to Receive $40M Upfront, Made Up to $20M Cash Payment, $20M Convertible Note Investment, Has Potential for Up to Added $275M in Milestone/Royalty Payments",2016-07-06 08:16:00-04:00,VRTX,neutral
1327296.0,"Vertex Pharma, Moderna Therapeutics Report Establishment of Exclusive Collab Deal for Discovery, Development of mRNA Therapeutics for CF",2016-07-06 08:15:00-04:00,VRTX,positive
1327297.0,"Vertex Pharmaceuticals' Recuperation Will Continue, Vetr Crowd Says",2016-06-16 14:00:00-04:00,VRTX,neutral
1327298.0,Vetr Crowd Says Buy Vertex Pharmaceuticals,2016-06-14 14:06:00-04:00,VRTX,neutral
1327299.0,Downside Ahead For Biotech Stocks?,2016-06-10 15:58:00-04:00,VRTX,negative
1327300.0,"Vertex Reports Data For ivacaftor and lumacaftor/ivacaftor, Data Shows LT Impact Of KALYDECO Across Multiple Measures Of Disease",2016-06-10 11:03:00-04:00,VRTX,neutral
1327301.0,Vertex Gets FDA's Priority Review For SNDA For Its ORKAMBI,2016-05-31 09:22:00-04:00,VRTX,neutral
1327302.0,"Vertex Pharmaceuticals Reports FDA Accepts sNDA For Review Of ORKAMBI, Target Date Of Sept. 30th",2016-05-31 08:00:00-04:00,VRTX,positive
1327303.0,Short Interest Surges In Illumina And Vertex Pharmaceuticals,2016-05-13 13:26:00-04:00,VRTX,positive
1327304.0,Vertex Pharmaceuticals Files for Potential Mixed Shelf; Size Not Disclosed,2016-05-03 17:15:00-04:00,VRTX,neutral
1327305.0,H.C. Wainwright: Vertex's Long-Term Value Is In The Pipeline,2016-04-28 11:57:00-04:00,VRTX,positive
1327306.0,"Short Sellers Dump Vertex, Load Up On Baxalta",2016-04-28 08:34:00-04:00,VRTX,negative
1327307.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-04-28 08:21:00-04:00,VRTX,neutral
1327308.0,"Goldman Sachs Downgrades Vertex Pharmaceuticals to Neutral, Lowers PT to $88.00, Removed From Americas Buy List",2016-04-28 06:44:00-04:00,VRTX,negative
1327309.0,Vertex Reports Q1 EPS $0.09 vs. Est. $0.29,2016-04-27 17:24:00-04:00,VRTX,neutral
1327310.0,"Earnings Scheduled For April 27, 2016",2016-04-27 04:01:00-04:00,VRTX,neutral
1327311.0,"Enterome Announces Has Signed Exclusive Global License Deal with Vertex Pharma for Research, Development, Commercialization of FimH Antagonists for Use in Treatment of IBD",2016-04-18 11:33:00-04:00,VRTX,negative
1327312.0,"After-Hours Recap: Active Rigs Count, Top Index Movers & More",2016-04-16 20:05:00-04:00,VRTX,positive
1327313.0,Option Alert: VRTX Jul16 97.5 Calls: 1000 @  ASK  $3.90: 1002 traded vs 10 OI:  Earnings 5/4  $83.92 Ref,2016-04-13 12:41:00-04:00,VRTX,positive
1327314.0,"Credit Suisse Maintains Outperform on Vertex Pharmaceuticals, Lowers PT to $112.00",2016-04-11 17:39:00-04:00,VRTX,positive
1327315.0,"After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More",2016-04-07 17:14:00-04:00,VRTX,neutral
1327316.0,Benzinga's Top Initiations,2016-04-07 08:53:00-04:00,VRTX,positive
1327317.0,BMO Capital Initiates Coverage on Vertex Pharmaceuticals at Market Perform,2016-04-07 06:29:00-04:00,VRTX,neutral
1327318.0,"After-Hours Recap: Bed Bath & Beyond, Apollo, Valeant, eBay & More",2016-04-06 18:36:00-04:00,VRTX,neutral
1327319.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-04-04 16:52:00-04:00,VRTX,neutral
1327320.0,Worst Stocks Of The First Quarter,2016-03-31 13:27:00-04:00,VRTX,negative
1327321.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-28 17:38:00-04:00,VRTX,neutral
1327322.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-23 16:40:00-04:00,VRTX,neutral
1327323.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-10 16:46:00-05:00,VRTX,neutral
1327324.0,"Vertex Receives Australian Approval for ORKAMBI (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",2016-03-08 15:05:00-05:00,VRTX,positive
1327325.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-02 16:22:00-05:00,VRTX,neutral
1327326.0,Vertex Reports Win of $1M in Grants to 18 Non-Profit Organizations to Advance Initiatives for People Living with CF,2016-02-24 09:06:00-05:00,VRTX,positive
1327327.0,Schroer: Biotech Will Turn Around,2016-02-13 22:12:00-05:00,VRTX,neutral
1327328.0,Oppenheimer Assumes Vertex Pharmaceuticals at Perform,2016-02-11 07:49:00-05:00,VRTX,neutral
1327329.0,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,2016-02-08 15:56:00-05:00,VRTX,positive
1327330.0,Analyst Sees 'No Reason' To Own MannKind,2016-02-08 13:07:00-05:00,VRTX,negative
1327331.0,Here's Why Shares Of Vertex Pharmaceuticals Tumbled,2016-02-05 14:09:00-05:00,VRTX,positive
1327332.0,Leerink Is Back On Board The Biotech Train,2016-02-05 10:32:00-05:00,VRTX,neutral
1327333.0,Vertex Pharma -4.6% Premarket @$87.50 Following Announcement of CRL by FDA,2016-02-05 08:04:00-05:00,VRTX,neutral
1327334.0,Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO in People with Cystic Fibrosis Ages 2 and Older,2016-02-05 08:01:00-05:00,VRTX,neutral
1327335.0,Leerink Swann Initiates Coverage on Vertex Pharmaceuticals at Outperform,2016-02-05 04:08:00-05:00,VRTX,neutral
1327336.0,"Jefferies Upgrades Vertex Pharmaceuticals to Buy, Lowers to $120.00",2016-02-01 06:17:00-05:00,VRTX,negative
1327337.0,"Street Likes Incyte & Vertex After Drug Trial, Earnings Update",2016-01-28 11:12:00-05:00,VRTX,positive
1327338.0,Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views,2016-01-28 10:06:00-05:00,VRTX,positive
1327339.0,Vertex Earlier Affirmed FY16 KALYDECO Sales $670M-$690M,2016-01-27 16:39:00-05:00,VRTX,neutral
1327340.0,"Vertex Reports Q4 EPS $0.17 vs. Est. $0.17, Rev. $417.935M vs. Est. $406.3M",2016-01-27 16:23:00-05:00,VRTX,neutral
1327341.0,"Earnings Scheduled For January 27, 2016",2016-01-27 04:05:00-05:00,VRTX,neutral
1327342.0,Vertex Pharma Reports Health Canada Approves ORKAMBI For Underlying Cause Of Cystic Fibrosis 12 Years And Older,2016-01-26 17:21:00-05:00,VRTX,positive
1327343.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,VRTX,positive
1327344.0,"Credit Suisse Initiates Coverage on Vertex Pharmaceuticals at Outperform, Announces $151.00 PT",2016-01-19 16:17:00-05:00,VRTX,positive
1327345.0,Benzinga's Top Initiations,2015-12-01 09:54:00-05:00,VRTX,positive
1327346.0,"Stifel: Buy Vetrex, Checks Predict Strong Orkambi Launch",2015-12-01 09:45:00-05:00,VRTX,positive
1327347.0,"Stifel Nicolaus Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces $125.00 PT",2015-12-01 08:25:00-05:00,VRTX,neutral
1327348.0,Vertex Appoints Michael J. Parini as EVP and Chief Legal Officer,2015-11-23 08:34:00-05:00,VRTX,positive
1327349.0,Vertex Receives EU Approval for ORKAMBI (lumacaftor/ivacaftor),2015-11-20 05:37:00-05:00,VRTX,positive
1327350.0,"Early Global News: ON Semiconductor To Buy Fairchild, Stratasys And Autos, Google Maps Vs. Yelp",2015-11-18 08:33:00-05:00,VRTX,neutral
1327351.0,Vertex Receives Two EU Approvals for KALYDECO for Cystic Fibrosis,2015-11-18 04:19:00-05:00,VRTX,neutral
1327352.0,Details in Vertex Pharma 10-Q Confirms DoJ Subpoena,2015-10-30 16:43:00-04:00,VRTX,neutral
1327353.0,Shares of Vertex Pharma Indicated Lower Following Chatter Co. Received DoJ Subpoena During Q3,2015-10-30 16:38:00-04:00,VRTX,neutral
1327354.0,Benzinga's Top Upgrades,2015-10-30 09:10:00-04:00,VRTX,positive
1327355.0,"H.C. Wainwright Upgrades Vertex Pharmaceuticals to Buy, Raises PT to $155.00",2015-10-30 07:13:00-04:00,VRTX,neutral
1327356.0,Morning Market Gainers,2015-10-29 09:47:00-04:00,VRTX,neutral
1327357.0,Benzinga's Top #PreMarket Gainers,2015-10-29 08:44:00-04:00,VRTX,positive
1327358.0,Vertex Raises FY15 KALYDECO Sales Outlook from $575M-$590M to $605M-$620M,2015-10-28 16:38:00-04:00,VRTX,neutral
1327359.0,"Vertex Pharmaceuticals Incorporated Reports Q3 Loss $0.13 Vs Est Loss $0.25, Sales $310M Vs Est $245.97M",2015-10-28 16:01:00-04:00,VRTX,negative
1327360.0,"Biotech ETFs: Buy, Buy, Buy?",2015-10-27 07:19:00-04:00,VRTX,neutral
1327361.0,"Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex",2015-10-20 12:00:00-04:00,VRTX,negative
1327362.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,VRTX,positive
1327363.0,UPDATE: Vertex Says Two Next-Gen Correctors to Enter Clinical Development in Nov; Studies of Triple Combo Planned for '16,2015-10-08 09:04:00-04:00,VRTX,neutral
1327364.0,Vertex Pharma Announces Progress in Development Efforts to Treat Cause of Cystic Fibrosis,2015-10-08 09:03:00-04:00,VRTX,positive
1327365.0,Vertex Announces sNDA for Use of KALYDECO Accepted for Priority Review,2015-10-07 16:53:00-04:00,VRTX,positive
1327366.0,Benzinga's Top Upgrades,2015-10-02 09:01:00-04:00,VRTX,positive
1327367.0,"Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant",2015-10-02 08:26:00-04:00,VRTX,negative
1327368.0,"Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight, Raises PT to $148.00",2015-10-02 04:09:00-04:00,VRTX,negative
1327369.0,Why Argus Upgraded Vertex Pharma To Buy Last Week,2015-09-29 08:07:00-04:00,VRTX,neutral
1327370.0,"Argus Research Upgrades Vertex Pharmaceuticals to Buy, Maintains $126.00 PT",2015-09-28 08:17:00-04:00,VRTX,neutral
1327371.0,"Vertex Announces Received CHMP Positive Opinion for ORKAMBI, KALYDECO in EU",2015-09-25 07:17:00-04:00,VRTX,positive
1327372.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,VRTX,positive
1327373.0,"Vertex Pharma's Orkambi Gives It Huge Potential, Says Barclays",2015-09-14 10:18:00-04:00,VRTX,positive
1327374.0,Morning Market Gainers,2015-09-14 09:39:00-04:00,VRTX,neutral
1327375.0,Benzinga's Top Upgrades,2015-09-14 09:25:00-04:00,VRTX,positive
1327376.0,Benzinga's Top #PreMarket Gainers,2015-09-14 08:15:00-04:00,VRTX,positive
1327377.0,"Barclays Favorite Biotech Names For Year End Balance Are Gilead, Vertex, Medivation",2015-09-14 07:11:00-04:00,VRTX,positive
1327378.0,US Stock Futures Signal Higher Start On Wall Street,2015-09-14 07:05:00-04:00,VRTX,neutral
1327379.0,"Barclays Upgrades Vertex Pharmaceuticals to Overweight, Raises PT to $150.00",2015-09-14 04:08:00-04:00,VRTX,negative
1327380.0,Biogen And Gilead Sciences Catch The Eye Of Short Sellers,2015-08-27 11:06:00-04:00,VRTX,neutral
1327381.0,4 Biotechs Piper Jaffray Is Buying On The Pullback,2015-08-26 15:27:00-04:00,VRTX,neutral
1327382.0,"Vertex Reports Q2 Loss $0.78 Vs Est Loss $0.58, Sales $166.1M Vs Est $149.70M, Kalydeco Revs TO Be $575-$590M In 2015",2015-07-29 16:37:00-04:00,VRTX,negative
1327383.0,Is More M&A On The Way For Large-Cap Biotechs?,2015-07-28 13:18:00-04:00,VRTX,neutral
1327384.0,CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton,2015-07-10 06:52:00-04:00,VRTX,neutral
1327385.0,Baird And Piper Jaffray Love Vertex: Here's Why,2015-07-07 14:56:00-04:00,VRTX,positive
1327386.0,"Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside",2015-07-06 08:34:00-04:00,VRTX,negative
1327387.0,Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call,2015-07-05 14:26:00-04:00,VRTX,neutral
1327388.0,CNBC's Stock Pops & Drops From July 2,2015-07-03 09:40:00-04:00,VRTX,neutral
1327389.0,"Shares of Vertex Pharma Down Sharply from Session High at $132, Now Trading at ~$128.80, Up Less Than 2% for Session",2015-07-02 15:10:00-04:00,VRTX,positive
1327390.0,UPDATE: Vertex Shares Trading Up 3.5% from Wednesday's Close,2015-07-02 15:00:00-04:00,VRTX,positive
1327391.0,Shares of Vertex Resume Trade; Now Trading Slightly Lower from Halt,2015-07-02 15:00:00-04:00,VRTX,positive
1327392.0,Shares of Vertex to Resume Trade at 3 p.m. EDT,2015-07-02 14:45:00-04:00,VRTX,positive
1327393.0,Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo ORKAMBI,2015-07-02 14:44:00-04:00,VRTX,positive
1327394.0,"ORKAMBI Price At $259K/Year, Est Was For $230-$250K - Vertex Pharma Announces On Conf. Call",2015-07-02 14:29:00-04:00,VRTX,neutral
1327395.0,Vertex Pharma Execs Currently Discussing ORKAMBI on Conference Call,2015-07-02 14:27:00-04:00,VRTX,neutral
1327396.0,The Cystic Fibrosis Foundation Issues Release Celebrating FDA Approval of Lumacaftor/Ivacaftor Combo Drug ORKAMBI,2015-07-02 14:11:00-04:00,VRTX,positive
1327397.0,UPDATE: Vertex Will Host Conference Call at 2:15 p.m. EDT to Offer More Info on Approval of ORKAMBI,2015-07-02 13:49:00-04:00,VRTX,positive
1327398.0,UPDATE: Vertex Release Confirms FDA Approval of ORKAMBI,2015-07-02 13:47:00-04:00,VRTX,positive
1327399.0,Vertex Release Confirms FDA Approval of ORKAMBI,2015-07-02 13:46:00-04:00,VRTX,positive
1327400.0,Goldman Comments On Vertex Pharmaceuticals Following FDA Approval,2015-07-02 13:41:00-04:00,VRTX,positive
1327401.0,"Goldman on Vertex:  We Await Orkambi Pricing Details, Expect To Be On Par WIth Kalydeco ($312K/Yr) Given Strong Secondary Endpoint And Historical Analysis Of Orphan Drug Pricing",2015-07-02 12:58:00-04:00,VRTX,positive
1327402.0,The Street's Adam Feuerstein Recently Highlighting Pricing for Vertex,2015-07-02 12:48:00-04:00,VRTX,neutral
1327403.0,Adam Feuerstein Tweets: 'We now wait for Orkambi price. $VRTX',2015-07-02 12:05:00-04:00,VRTX,neutral
1327404.0,Vertex Wins US Approval For Cystic Fibrosis Combo Orkambi,2015-07-02 12:00:00-04:00,VRTX,positive
1327405.0,Vertex Shares Halted News Pending,2015-07-02 11:48:00-04:00,VRTX,positive
1327406.0,Benzinga's Top #PreMarket Gainers,2015-06-26 08:11:00-04:00,VRTX,positive
1327407.0,"Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors",2015-06-18 16:01:00-04:00,VRTX,neutral
1327408.0,"Vertex Pharma Offers Data Presentations at ECFS Conference: TRAFFIC, TRANSPORT Extension Study of Lumacaftor Im Combo with Ivacaftor Showed Improvements",2015-06-11 09:04:00-04:00,VRTX,positive
1327409.0,"Vertex Pharmaceuticals Will Outperform, Has 'Competitive Edge,' JMP Says",2015-06-08 04:09:00-04:00,VRTX,positive
1327410.0,"Vertex Announces Collaboration with Parion Sciences to Develop ENaC Inhitibors in CF, Pulmonary Diseases",2015-06-04 16:02:00-04:00,VRTX,neutral
1327411.0,Vertex Pharmaceuticals Announces NEJM Publishes Data from Two Phase 3 Studies of ORKAMBITM,2015-05-17 17:52:00-04:00,VRTX,neutral
1327412.0,"JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval",2015-05-13 13:55:00-04:00,VRTX,positive
1327413.0,Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts,2015-05-13 10:26:00-04:00,VRTX,positive
1327414.0,Morning Market Gainers,2015-05-13 09:50:00-04:00,VRTX,neutral
1327415.0,Benzinga's Top #PreMarket Gainers,2015-05-13 08:13:00-04:00,VRTX,positive
1327416.0,"Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More",2015-05-12 21:22:00-04:00,VRTX,neutral
1327417.0,Shares of Vertex to Resume Trade at 4:45 p.m. EDT,2015-05-12 16:20:00-04:00,VRTX,positive
1327418.0,Vertex Release Confirms FDA Panel Voted 12-1 to Recommend Approval of ORKAMBI for Treatment of Cystic Fibrosis,2015-05-12 16:16:00-04:00,VRTX,positive
1327419.0,Vertex's Orkambi Gains Backing Of U.S. FDA Advisers,2015-05-12 15:44:00-04:00,VRTX,positive
1327420.0,FDA Advisory Panel Vote Inconclusive on Whether Vertex's Lumacaftor Contributes Positively to Orkambi's Effectiveness,2015-05-12 15:30:00-04:00,VRTX,positive
1327421.0,UPDATE: Shares of Vertex Currently Halted Up ~0.75% to $125.05 Ahead of FDA Advisory Panel to Review Cystic Fibrosis Combo,2015-05-12 07:51:00-04:00,VRTX,positive
1327422.0,Vertex Pharma Shares Halted News Pending,2015-05-12 07:00:00-04:00,VRTX,positive
1327423.0,Why Fears Of Biotech Being Overvalued Are Unwarranted,2015-05-09 15:45:00-04:00,VRTX,negative
1327424.0,Vertex Shares Moving Lower as FDA Issues Results of May 12 Panel Related to Ivacaftor/Lumacaftor Combo,2015-05-08 08:07:00-04:00,VRTX,neutral
1327425.0,Is Gilead Sciences About To Buy Vertex For $45 Billion?,2015-04-30 11:57:00-04:00,VRTX,neutral
1327426.0,"Vertex Pharma Reports Q1 Adj. Loss of $0.62/Share vs Loss of $0.75/Share Est., Sales $138.5M vs $142.4M Est.",2015-04-29 16:08:00-04:00,VRTX,negative
1327427.0,What's Wall Street Been Saying About Gilead Lately?,2015-04-29 12:34:00-04:00,VRTX,neutral
1327428.0,Veritex Holdings Reports Q1 EPS $0.19 Vs Est $0.17,2015-04-29 07:02:00-04:00,VRTX,neutral
1327429.0,3 Biotech Stocks With Rising Short Interest,2015-04-28 07:32:00-04:00,VRTX,positive
1327430.0,Oppenheimer Assumes Vertex Pharmaceuticals at Perform,2015-04-27 07:55:00-04:00,VRTX,neutral
1327431.0,"Benzinga's M&A Chatter for Tuesday April 21, 2015",2015-04-21 19:37:00-04:00,VRTX,neutral
1327432.0,"Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says",2015-04-21 12:57:00-04:00,VRTX,negative
1327433.0,Adam Feuerstein @adamfeuerstein Tweet: Ackman could be interviewed on @CNBC multiple times across many shows to promote/pump his $GILD position.,2015-04-21 12:42:00-04:00,VRTX,neutral
1327434.0,Should Gilead Buy Vertex?,2015-04-21 11:44:00-04:00,VRTX,neutral
1327435.0,Hearing RBC Says Probability of Gilead Buying Vertex is Low,2015-04-21 11:23:00-04:00,VRTX,negative
1327436.0,RBC Analyst Saying Gilead and Vertex Deal Is A 'pretty low probability',2015-04-21 11:21:00-04:00,VRTX,positive
1327437.0,"Tweet, Rumor And Bernstein Fueling Rallies In Gilead Sciences, Vertex Pharmaceuticals",2015-04-21 11:01:00-04:00,VRTX,neutral
1327438.0,Hearing Unconfirmed Market Chatter of Ackman $2B Stake in Gilead; Ackman Said to Push for Acquisition of Vertex,2015-04-21 09:48:00-04:00,VRTX,negative
1327439.0,Bernstein: It's Time For Gilead To Pull The Trigger On This Acquisition,2015-04-21 09:23:00-04:00,VRTX,neutral
1327440.0,"Adam Feuerstein @adamfeuerstein Tweet: $GILD Should Buy $VRTX for $45B Now, Analyst Says thestreet.com/story/13119465 via @TheStreet",2015-04-21 08:25:00-04:00,VRTX,neutral
1327441.0,Is This Stock A Vertex Pharma Clone?,2015-04-10 20:54:00-04:00,VRTX,neutral
1327442.0,Benzinga's Top Initiations,2015-04-10 09:06:00-04:00,VRTX,positive
1327443.0,Canaccord Genuity Initiates Vertex Pharmaceuticals At Buy,2015-04-10 08:43:00-04:00,VRTX,neutral
1327444.0,"Canaccord Genuity Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces $150.00 PT",2015-04-10 05:31:00-04:00,VRTX,neutral
1327445.0,Is It Closing Time At The Biotech Bar?,2015-03-26 13:45:00-04:00,VRTX,neutral
1327446.0,Morgan Stanley Talks New Vertex Data,2015-03-24 16:20:00-04:00,VRTX,neutral
1327447.0,"Vertex Treatment May Have High Risk of Failure, Analyst Suggests",2015-03-24 15:13:00-04:00,VRTX,negative
1327448.0,Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Results Isn't The End,2015-03-23 19:03:00-04:00,VRTX,negative
1327449.0,ICYMI: Pharmaceutical Stocks Are Moving Big On Monday,2015-03-23 12:13:00-04:00,VRTX,neutral
1327450.0,"Deutsche Bank Analyst Suggests Buy Vertex Shares on Weakness, Reiterates Buy, $155 Price Target",2015-03-23 10:38:00-04:00,VRTX,negative
1327451.0,Morning Market Losers,2015-03-23 10:02:00-04:00,VRTX,negative
1327452.0,Benzinga's Top #PreMarket Losers,2015-03-23 08:15:00-04:00,VRTX,negative
1327453.0,Vertex Reports Data from 12-Week Phase 2 Safety Study of VX-661 in Combo with Ivacaftor: Shows Combo Generally Well Tolerated,2015-03-23 07:47:00-04:00,VRTX,positive
1327454.0,Maxim: Our Vertex Pharma Thesis Is Unchanged,2015-03-20 11:29:00-04:00,VRTX,neutral
1327455.0,Vertex Recieves FDA Approval Of KALYDECO For Cystic Fibrosis In Children From 2-5 Years Old With Special Mutation In CFTR Gene,2015-03-18 07:47:00-04:00,VRTX,positive
1327456.0,Short Sellers Still Attracted To Biotech Stocks,2015-03-13 12:17:00-04:00,VRTX,positive
1327457.0,"UPDATE: Veritex Holdings to Acquire IBT Bancorp for ~1.185M Shares of Veritex Stock, $4M in Cash",2015-03-09 05:02:00-04:00,VRTX,positive
1327458.0,"Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst",2015-03-05 16:02:00-05:00,VRTX,positive
1327459.0,Short Sellers Come Back To Biotech Stocks,2015-02-26 13:25:00-05:00,VRTX,neutral
1327460.0,"UPDATE: Hearing Now that Vertex is Not Interested in PTC Therapeutics, They are Interested in a Cystic Fibrosis Play, PTC is Not a Major Cystic Fibrosis Play",2015-02-24 14:47:00-05:00,VRTX,positive
1327461.0,Hearing Unconfirmed Market Chatter of Vertex Interest in PTC Therapeutics,2015-02-24 14:42:00-05:00,VRTX,positive
1327462.0,Short Sellers Retreat From Biotech Stocks,2015-02-12 08:23:00-05:00,VRTX,positive
1327463.0,Baird Releases Comments After Vertex Earnings Call,2015-01-29 15:08:00-05:00,VRTX,neutral
1327464.0,Maxim Downgrades Vertex Pharmaceuticals After Earnings,2015-01-29 12:00:00-05:00,VRTX,neutral
1327465.0,Morning Market Losers,2015-01-29 10:00:00-05:00,VRTX,negative
1327466.0,Benzinga's Top #PreMarket Losers,2015-01-29 08:20:00-05:00,VRTX,negative
1327467.0,Vertex Pharmaceuticals Beats Q4 Revenue Expectations,2015-01-28 17:39:00-05:00,VRTX,neutral
1327468.0,Vertex Pharma Reported Q4 Adj. Loss of $0.55/Share,2015-01-28 16:33:00-05:00,VRTX,negative
1327469.0,Vertex Reports Q4 Loss Of -0.74 Vs. Est. Loss Of $0.65,2015-01-28 16:03:00-05:00,VRTX,negative
1327470.0,"Earnings Scheduled For January 28, 2015",2015-01-28 05:02:00-05:00,VRTX,neutral
1327471.0,5 Big Biotech Earnings Releases To Watch This Week,2015-01-26 14:34:00-05:00,VRTX,neutral
1327472.0,Vertex Pharma Says Horton Now Acting As Special Counsel To CEO,2015-01-20 17:01:00-05:00,VRTX,positive
1327473.0,"Vertex CEO On Company's New Cystic Fibrosis Drug, Pricing Strategy",2015-01-14 10:40:00-05:00,VRTX,neutral
1327474.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,VRTX,neutral
1327475.0,Vertex Sees Kalydeco FY Revenue $560M-$580M,2015-01-11 20:58:00-05:00,VRTX,neutral
1327476.0,Adam Feuerstein @adamfeuerstein Tweet: $GILD Buying $VRTX Among Bold Biotech Stock Predictions for 2015 thestreet.com/story/13006004 @dsobek peers into his Cajun crystal ball...,2015-01-09 10:55:00-05:00,VRTX,positive
1327477.0,J.P Morgan Just Chimed In With Ratings On Biotech Stocks,2015-01-06 16:34:00-05:00,VRTX,neutral
1327478.0,UPDATE: Barclays Capital Initiates Coverage On Vertex Pharmaceuticals On Leading Position In CF Market,2015-01-06 10:24:00-05:00,VRTX,neutral
1327479.0,"Barclays Initiates Coverage on Vertex Pharmaceuticals at Equal-weight, Announces $120.00 PT",2015-01-06 06:18:00-05:00,VRTX,neutral
1327480.0,"BTIG Initiates Coverage On Vertex Pharmaceuticals, Notes Company's Cystic Fibrosis Therapies",2015-01-05 19:11:00-05:00,VRTX,neutral
1327481.0,"BTIG Research Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces $200.00 PT",2015-01-05 17:28:00-05:00,VRTX,neutral
1327482.0,U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation,2014-12-29 15:11:00-05:00,VRTX,positive
1327483.0,U.S. Food and Drug Administration Approves KALYDECO for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation,2014-12-29 15:11:00-05:00,VRTX,positive
1327484.0,William Blair's Top BioPharma Stock Picks For Q1 2015,2014-12-26 16:51:00-05:00,VRTX,positive
1327485.0,Benzinga's Top #PreMarket Losers,2014-12-22 08:18:00-05:00,VRTX,negative
1327486.0,"Vertex Reports Naming of David Altshuler as Exec VP, Global Research, Chief Scientific Officer",2014-12-15 09:04:00-05:00,VRTX,neutral
1327487.0,Don't Overlook Mid-Cap Stocks,2014-12-11 18:14:00-05:00,VRTX,neutral
1327488.0,"Great News For Biogen, But What's Next For The Stock?",2014-12-03 12:36:00-05:00,VRTX,positive
1327489.0,Adam F Says Royalty Pharma's $3.3B Deal for Rights to Cystic Fibrosis Drugs is Bullish for Vertex,2014-11-19 13:31:00-05:00,VRTX,neutral
1327490.0,Royalty Pharma Reports Purchase of Acquisition of Royalties on Vertex Pharma's CF Treatments  Owned by CFFT for $3.3B in Cash,2014-11-19 07:29:00-05:00,VRTX,neutral
1327491.0,"Vertex Submits Applications in US, Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of  F508del Mutation ",2014-11-05 07:10:00-05:00,VRTX,positive
1327492.0,Vertex Submits Applications In The U.S. And Europe For Approval Of Lumacaftor In Combination With Ivacaftor ,2014-11-05 07:03:00-05:00,VRTX,positive
1327493.0,"JMP Securities Maintains Market Perform on Vertex Pharmaceuticals Incorporated, Raises PT to $133.00",2014-10-29 09:04:00-04:00,VRTX,positive
1327494.0,Vertex Pharmaceuticals Incorporated Reports Q3 EPS of $(0.37) vs $(0.63) Est; Revenue of $179.0M vs $146.95M Est,2014-10-28 16:04:00-04:00,VRTX,neutral
1327495.0,Vertex Energy Agrees to Acquire Substantially All Assets of Heartland Group Holdings -8-K,2014-10-28 06:13:00-04:00,VRTX,positive
1327496.0,"Earnings Scheduled For October 28, 2014",2014-10-28 05:25:00-04:00,VRTX,neutral
1327497.0,FDA Advisory Committee Recommends Approval of KALYDECO ,2014-10-21 16:48:00-04:00,VRTX,positive
1327498.0,"Vertex Has Won FDA Panel Vote for Kalydeco, Vote for Safety Was 14-1 In Favor, Vote for Approval 13-2",2014-10-21 15:21:00-04:00,VRTX,positive
1327499.0,FDA Advisory Panel Has Voted Vertex's Kalydeco is Safe for R117H Mutation,2014-10-21 15:16:00-04:00,VRTX,positive
1327500.0,"FDA Reviews Vertex Pharma's KALYDECO for CF with R117H Mutation, Publishes Report for Oct. 21 Panel Meeting",2014-10-17 07:56:00-04:00,VRTX,neutral
1327501.0,Hearing Bank of America Merrill Lynch Cautious on Vertex,2014-10-14 13:58:00-04:00,VRTX,negative
1327502.0,Bank Of America Is Impressed By Takeaways From Vertex Pharmaceuticals Conference Call,2014-10-14 07:59:00-04:00,VRTX,positive
1327503.0,UPDATE: Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals,2014-10-13 08:45:00-04:00,VRTX,neutral
1327504.0,Big Swings in Biotech Short Interest,2014-10-13 08:32:00-04:00,VRTX,positive
1327505.0,Benzinga's Top Upgrades,2014-10-13 08:30:00-04:00,VRTX,positive
1327506.0,Piper Jaffray Upgrades Vertex Pharmaceuticals To Overweight,2014-10-13 08:09:00-04:00,VRTX,negative
1327507.0,"Piper Jaffray Upgrades Vertex Pharmaceuticals Incorporated to Overweight, Raises PT to $125.00",2014-10-13 06:29:00-04:00,VRTX,negative
1327508.0,Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis ,2014-10-09 09:32:00-04:00,VRTX,positive
1327509.0,"Guggenheim Securities Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces $147.00 PT",2014-10-02 06:07:00-04:00,VRTX,positive
1327510.0,H.C. Wainwright Highlights Its Top Picks Ahead Of NACFC 2014,2014-10-01 10:15:00-04:00,VRTX,positive
1327511.0,"Fast Money Picks For September 26 - Pfizer Inc., The Dow Chemical Company And More",2014-09-25 20:26:00-04:00,VRTX,neutral
1327512.0,Stocks Hitting 52-Week Highs,2014-09-24 09:58:00-04:00,VRTX,neutral
1327513.0,These 3 Biotech Stocks Just Hit New Highs,2014-09-22 13:31:00-04:00,VRTX,neutral
1327514.0,"Midday Gainers From September 19 - Alibaba Group Holding Ltd, Concur Technologies, Inc. And More",2014-09-19 14:13:00-04:00,VRTX,neutral
1327515.0,"Deutsche Bank Boosts Target on Vertex Pharma from $103 to $127, Buy Maintained",2014-09-16 14:21:00-04:00,VRTX,positive
1327516.0,Benzinga's Top Upgrades,2014-09-08 08:54:00-04:00,VRTX,positive
1327517.0,Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy,2014-09-08 07:59:00-04:00,VRTX,neutral
1327518.0,"Goldman Sachs Upgrades Vertex Pharmaceuticals Incorporated to Buy, Raises PT to $131.00",2014-09-08 06:05:00-04:00,VRTX,neutral
1327519.0,Vertex Receives EC Approval for KALYDECO in Eight Non-G551D Gating Mutations ,2014-07-31 16:31:00-04:00,VRTX,positive
1327520.0,Vertex Pharmaceuticals: Analysts Offer Insight On Business Developments,2014-07-30 16:54:00-04:00,VRTX,neutral
1327521.0,"Vertex Pharma Reports Q2 Loss of $0.68/Share, Sales $138.4M; Reaffirms FY Outlook",2014-07-29 16:18:00-04:00,VRTX,negative
1327522.0,Vertex Is Poised For An Earnings Breakout,2014-07-23 15:56:00-04:00,VRTX,positive
1327523.0,Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Market Perform,2014-07-08 06:24:00-04:00,VRTX,neutral
1327524.0,Vertex Announces sNDA to FDA for Kaldeco,2014-06-30 16:06:00-04:00,VRTX,neutral
1327525.0,Vertex Shares Edge Higher as FDA Indicates Orphan Drug Designation for lumacaftor and ivacaftor,2014-06-30 14:03:00-04:00,VRTX,positive
1327526.0,Vertex Announces Positive Opinion For Kalydeco From European CHMP,2014-06-27 07:15:00-04:00,VRTX,positive
1327527.0,"Adam Feuerstein Tweet: Mad About Missing $VRTX Big Move? Don't Be, The Stock Is Still Undervalued > thestreet.com/story/12756325",2014-06-25 11:31:00-04:00,VRTX,negative
1327528.0,Analyst Concerns On Vertex's Approved Drug,2014-06-25 09:14:00-04:00,VRTX,positive
1327529.0,Benzinga's Top Downgrades,2014-06-25 08:00:00-04:00,VRTX,positive
1327530.0,HC Wainwright Downgrades Vertex Pharmaceuticals Incorporated to Neutral,2014-06-25 07:21:00-04:00,VRTX,neutral
1327531.0,Consumer Confidence And Housing Data Take A Back-Seat To Markets,2014-06-24 16:36:00-04:00,VRTX,positive
1327532.0,Utility Sector Rises; Elizabeth Arden Shares Slide Over 3.6%,2014-06-24 15:15:00-04:00,VRTX,positive
1327533.0,UBS Analyst Comments On Vertex's Combination Regimen,2014-06-24 12:39:00-04:00,VRTX,neutral
1327534.0,Micron Gains On Upbeat Earnings; Elizabeth Arden Shares Slide,2014-06-24 12:36:00-04:00,VRTX,positive
1327535.0,Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release,2014-06-24 11:36:00-04:00,VRTX,neutral
1327536.0,Bernstein Weighs In On Vertex Move,2014-06-24 10:58:00-04:00,VRTX,neutral
1327537.0,Benzinga's Volume Movers,2014-06-24 10:41:00-04:00,VRTX,neutral
1327538.0,Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Misses Estimates,2014-06-24 10:28:00-04:00,VRTX,positive
1327539.0,Stocks Hitting 52-Week Highs,2014-06-24 10:20:00-04:00,VRTX,neutral
1327540.0,Morning Market Movers ,2014-06-24 09:40:00-04:00,VRTX,neutral
1327541.0,Why Is Vertex Pharmaceuticals Up More Than 50 Percent?,2014-06-24 08:27:00-04:00,VRTX,neutral
1327542.0,Benzinga's Top #PreMarket Gainers,2014-06-24 08:07:00-04:00,VRTX,positive
1327543.0,"Vertex Pharma Shares Resume Trade, Now Up Nearly 43%",2014-06-24 07:30:00-04:00,VRTX,positive
1327544.0,Shares of Vertex Pharma to Resume Trade at 7:30 a.m. EDT,2014-06-24 07:07:00-04:00,VRTX,positive
1327545.0,UPDATE: Vertex Pharma Announces Primary Endpoint Was Met for Lumacaftor Study,2014-06-24 07:03:00-04:00,VRTX,neutral
1327546.0,"Vertex Says Two 24-Week Phase 3 Studies of Lumacaftor in Combo with Ivacaftor Met Primary Endpoint, Statistically Significant Improvements",2014-06-24 07:00:00-04:00,VRTX,positive
1327547.0,Vertex Pharma Halted News Pending,2014-06-24 06:58:00-04:00,VRTX,neutral
1327548.0,J&J's Janssen Announces License Deal with Vertex to Develop Novel Treatment for Influenza A,2014-06-18 08:32:00-04:00,VRTX,positive
1327549.0,"Vertex Licenses VX-787 to Janssen Pharma, Vertex to Receive $30M Upfront",2014-06-18 08:30:00-04:00,VRTX,neutral
1327550.0,Vertex Reports Signed Letter of Intent to Enable Public Reimbursement of KALYDECO in Canada,2014-06-16 17:15:00-04:00,VRTX,neutral
1327551.0,Vertex Shares Hit Hard On Trial Concerns,2014-06-16 13:39:00-04:00,VRTX,positive
1327552.0,"Mid-Day Market Movers For Monday, June 16, 2014",2014-06-16 12:52:00-04:00,VRTX,neutral
1327553.0,Benzinga's Top #PreMarket Losers,2014-06-16 08:16:00-04:00,VRTX,negative
1327554.0,"Vertex Releases New Data on KALYDECO, Says Shows Loss of Lung Function Reduced by Half Over Three Years",2014-06-12 09:03:00-04:00,VRTX,negative
1327555.0,Vertex Pharmaceuticals Announces Positive Results From First Two Week of Cystic Fibrosis Treatment,2014-06-04 08:03:00-04:00,VRTX,positive
1327556.0,"Option Alert: Vertex Jul $70/$100 Call Spread; 2,994 Spread Trade; Currently $65.95",2014-05-20 10:16:00-04:00,VRTX,positive
1327557.0,Vertex Pharmaceuticals Incorporated Reports Q1 EPS of $(1.00) vs $(0.68) Est,2014-05-01 16:02:00-04:00,VRTX,neutral
1327558.0,FDA Reports Orphan Drug Designation for Vertex's CF Treatment - Bloomberg,2014-04-25 11:02:00-04:00,VRTX,neutral
1327559.0,"Option Alert: Jun $75 Call; 2,500 Contracts Traded vs 71 OI; Currenlty $66.96",2014-04-09 11:33:00-04:00,VRTX,positive
1327560.0,"Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016",2014-04-08 08:11:00-04:00,VRTX,neutral
1327561.0,FDA Approves Vertex's Kalydeco for Use in Eight Added Mutations,2014-02-21 14:56:00-05:00,VRTX,positive
1327562.0,Adam Feuerstein Tweet:$VRTX Swaps Endpoints in Key Cystic Fibrosis Studies > thestreet.com/story/12438631,2014-02-21 14:20:00-05:00,VRTX,neutral
1327563.0,Vertex Pharmaceuticals Incorporated Sees FY2014 Sales $570.0M-600.0M vs $621.0M Est,2014-01-29 16:33:00-05:00,VRTX,neutral
1327564.0,Vertex Pharmaceuticals Incorporated Reports Q4 EPS of $0.19; Revenue of $351.20M,2014-01-29 16:04:00-05:00,VRTX,neutral
1327565.0,Vertex CEO Says Considering Sale of Hepatitis C Drug -Scrip Intelligence,2014-01-15 06:38:00-05:00,VRTX,positive
1327566.0,"UPDATE: Vertex Sees FY14 Adj. Oper. Costs $900-950M, Sees Kalydeco Sales $470-500M",2014-01-13 16:51:00-05:00,VRTX,neutral
1327567.0,Form 8-K from Vertex Pharma Shows Co. Expecting FY14 Net Sales $570-600M vs $660M Est.,2014-01-13 16:49:00-05:00,VRTX,neutral
1327568.0,Vertex Sees 2014 Net Revenues $570M-$600M,2014-01-12 19:18:00-05:00,VRTX,neutral
1327569.0,Vertex Reports Sustained Viral Response 83% in Treatment-Naive Genotype 1 on Combo with Daclatasvir for HCV,2014-01-09 08:35:00-05:00,VRTX,neutral
1327570.0,UBS Upgrades Vertex Pharmaceuticals Incorporated to Buy,2014-01-06 07:59:00-05:00,VRTX,neutral
1327571.0,Benzinga's Top #PreMarket Losers,2013-12-19 08:27:00-05:00,VRTX,negative
1327572.0,Vertex Pharma Says Phase 3 Study Results of Ivacaftor Did Not Meet Primary Endpoint,2013-12-19 07:33:00-05:00,VRTX,neutral
1327573.0,"EMA Says Will Discuss Extension of Indication for Merck's Noxafil, Isentress, Pfizer's Vfend, Amgen's Xgeva, Vertex Pharma's Kalydeco",2013-12-17 11:55:00-05:00,VRTX,neutral
1327574.0,Trade Idea of the Day: Short Vertex,2013-12-11 15:36:00-05:00,VRTX,neutral
1327575.0,Form 8-K from Vertex Pharma Shows J&J's Janssen Will Make $152M Payment Related to Incivo Sales Royalties During Q4,2013-11-22 16:22:00-05:00,VRTX,neutral
1327576.0,"US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data",2013-11-20 07:00:00-05:00,VRTX,negative
1327577.0,Vertex Sells INCIVO Product Royalty Rights to  Janssen Pharmaceutica for $152M,2013-11-20 05:46:00-05:00,VRTX,neutral
1327578.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,VRTX,positive
1327579.0,Summer Street Downgrades Vertex Pharmaceuticals Incorporated to Neutral,2013-10-30 08:23:00-04:00,VRTX,neutral
1327580.0,BofA Raises Price Target on Vertex from $103 to $111,2013-10-29 13:25:00-04:00,VRTX,neutral
1327581.0,"Vertex Pharma Reports Q3 Adj. Loss of $0.32/Share vs Loss of $0.35/Share Est.; Says Will Cut 370 Jobs, Expecting $35-45M Charge",2013-10-29 08:05:00-04:00,VRTX,negative
1327582.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,VRTX,positive
1327583.0,Vertex Announces Oral Selective JAK3 Inhibitor VX-509 Shows Statistically Significant Improvement in RA Phase 2b Study ,2013-10-18 17:45:00-04:00,VRTX,positive
1327584.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,VRTX,neutral
1327585.0,Vertex Issues sNDA for KALYDECO,2013-09-30 08:03:00-04:00,VRTX,neutral
1327586.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,VRTX,positive
1327587.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,VRTX,positive
1327588.0,"Vertex, Ametek to Join S&P 500, AMD, SAIC to Join MidCap 400, Capstead to Join SmallCap 600",2013-09-11 17:24:00-04:00,VRTX,positive
1327589.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,VRTX,positive
1327590.0,"Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Outperform, Announces $105.00 PT",2013-08-21 16:28:00-04:00,VRTX,neutral
1327591.0,"Oppenheimer Initiates Coverage on Vertex Pharmaceuticals Incorporated at Outperform, Announces $105.00 PT",2013-08-21 16:17:00-04:00,VRTX,neutral
1327592.0,UPDATE: Vertex Updates Recent Progress and Upcoming Milestones in Clinical Development Programs ,2013-07-29 16:02:00-04:00,VRTX,positive
1327593.0,Vertex Pharmaceuticals Incorporated Reports Q2 EPS of $(0.03) Which May Not Compare $(0.18) Est; Revenue of $311.0M Which May Not Compare $308.02M Est,2013-07-29 16:01:00-04:00,VRTX,neutral
1327594.0,"Market Wrap for Friday, July 26: Stocks Grind Out Small Gains to Close Week",2013-07-26 16:26:00-04:00,VRTX,positive
1327595.0,"Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected",2013-07-26 16:05:00-04:00,VRTX,neutral
1327596.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,VRTX,positive
1327597.0,UBS Downgrades Vertex Pharmaceuticals to Neutral,2013-07-26 07:45:00-04:00,VRTX,neutral
1327598.0,"Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight",2013-07-26 06:41:00-04:00,VRTX,neutral
1327599.0,Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C ,2013-07-25 16:04:00-04:00,VRTX,neutral
1327600.0,"Kris Jenner of Rock Springs Capital Mentioning Vertex, Gilead, Pharmacyclics",2013-07-17 15:52:00-04:00,VRTX,neutral
1327601.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,VRTX,positive
1327602.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,VRTX,positive
1327603.0,"Jefferies Says Analysis on Elan Supports $19/Share Takeover Bid, Lifts Price Target to $19",2013-06-18 10:39:00-04:00,VRTX,positive
1327604.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,VRTX,positive
1327605.0,"Vertex Shares Move Higher, May be Attributed to Positive Street.com Article",2013-06-11 10:29:00-04:00,VRTX,positive
1327606.0,"Mid-Afternoon Market Update: Markets Cool Off Slightly, Vertex Rises",2013-06-07 15:39:00-04:00,VRTX,positive
1327607.0,Vertex Says Company has Issued No News to Account for Strength in Stock Price Today,2013-06-07 14:37:00-04:00,VRTX,positive
1327608.0,Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection ,2013-05-30 08:03:00-04:00,VRTX,neutral
1327609.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,VRTX,positive
1327610.0,"Wunderlich Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces $4.00 PT",2013-05-17 08:40:00-04:00,VRTX,neutral
1327611.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,VRTX,positive
1327612.0,S&P Highlights Biotech ETFs,2013-05-10 07:39:00-04:00,VRTX,neutral
1327613.0,"UBS Maintains Buy on Vertex Pharmaceuticals Incorporated, Raises PT to $86.00",2013-05-01 10:23:00-04:00,VRTX,neutral
1327614.0,"Benzinga Market Primer: Wednesday, May 1",2013-05-01 06:37:00-04:00,VRTX,neutral
1327615.0,Vertex Pharmaceuticals Incorporated Reports Q1 EPS of $0.03 vs $(0.19) Est; Revenue of $328.40M vs $308.02M Est,2013-04-30 16:04:00-04:00,VRTX,neutral
1327616.0,"Benzinga Market Primer: Tuesday, April 30",2013-04-30 06:38:00-04:00,VRTX,neutral
1327617.0,Weekly Preview: Focus Shifts from Earnings to Economy,2013-04-26 16:35:00-04:00,VRTX,neutral
1327618.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,VRTX,neutral
1327619.0,Edison Investment Research Comments on Vertex Pharmaceuticals' VX-661 Data,2013-04-26 12:43:00-04:00,VRTX,neutral
1327620.0,"Benzinga's M&A Chatter for Thursday April 25, 2013",2013-04-25 19:46:00-04:00,VRTX,neutral
1327621.0,Hearing Unconfirmed Chatter of Vertex Interest in Sarepta,2013-04-25 09:35:00-04:00,VRTX,positive
1327622.0,Vertex Says New Data Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment ,2013-04-24 08:34:00-04:00,VRTX,neutral
1327623.0,"ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection ",2013-04-23 08:31:00-04:00,VRTX,positive
1327624.0,"Morgan Stanley Maintains Equal-weight on Vertex Pharmaceuticals Incorporated, Raises PT to $91.00",2013-04-22 08:40:00-04:00,VRTX,neutral
1327625.0,"Market Wrap for Friday, April 19: S&P 500 and Nasdaq Composite Jump; Dow Lags After IBM Earnings ",2013-04-19 16:30:00-04:00,VRTX,negative
1327626.0,Mid-Afternoon Market Update: The Dow Turns Green; Chipotle Continues to Rise,2013-04-19 15:42:00-04:00,VRTX,neutral
1327627.0,"Mid-Day Market Update: Celanese Jumps On Upbeat Results, Rambus Declines",2013-04-19 13:16:00-04:00,VRTX,neutral
1327628.0,UPDATE: Deutsche Bank Raises PT on Vertex Pharmaceuticals on 661 Data,2013-04-19 11:21:00-04:00,VRTX,neutral
1327629.0,Vertex News Lifts Biotech ETFs,2013-04-19 10:52:00-04:00,VRTX,neutral
1327630.0,Stocks Hitting 52-Week Highs,2013-04-19 10:37:00-04:00,VRTX,neutral
1327631.0,"Mid-Morning Market Update: Markets Mixed, General Electric Q1 Profit Surges 16%",2013-04-19 10:02:00-04:00,VRTX,positive
1327632.0,UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking,2013-04-19 09:45:00-04:00,VRTX,positive
1327633.0,"Option Alert: Vertex April 60 Call Rises 45,000%",2013-04-19 09:40:00-04:00,VRTX,positive
1327634.0,UPDATE: Goldman Sachs Upgrades Vertex Pharmaceuticals to Neutral on '661/Kalydeco Data,2013-04-19 08:54:00-04:00,VRTX,neutral
1327635.0,UPDATE: Canaccord Upgrades Vertex Pharmaceuticals to Buy Following Release of VX-661 Data,2013-04-19 08:54:00-04:00,VRTX,neutral
1327636.0,Benzinga's Top Upgrades,2013-04-19 07:36:00-04:00,VRTX,positive
1327637.0,"Citigroup Maintains Buy on Vertex Pharmaceuticals Incorporated, Raises PT to $100.00",2013-04-19 06:35:00-04:00,VRTX,neutral
1327638.0,"Goldman Sachs Upgrades Vertex Pharmaceuticals Incorporated to Neutral, Raises PT to $86.00",2013-04-19 06:25:00-04:00,VRTX,neutral
1327639.0,"Canaccord Genuity Upgrades Vertex Pharmaceuticals Incorporated to Buy, Raises PT to $96.00",2013-04-19 06:24:00-04:00,VRTX,neutral
1327640.0,Vertex Rises $30 After-Hours on Positive Cystic Fibrosis Data,2013-04-18 16:35:00-04:00,VRTX,positive
1327641.0,Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation ,2013-04-18 16:01:00-04:00,VRTX,positive
1327642.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,VRTX,neutral
1327643.0,UPDATE: Canaccord Initiates Vertex Pharmaceuticals with Hold  on VX-809/Kalydeco Combination Therapy,2013-04-08 08:23:00-04:00,VRTX,neutral
1327644.0,"Canaccord Genuity Initiates Coverage on Vertex Pharmaceuticals Incorporated at Hold, Announces $55.00 PT",2013-04-08 06:05:00-04:00,VRTX,neutral
1327645.0,"Vertex, Bristol-Myers Enter Deal for Phase 2 All-Oral Studies of VX-135",2013-04-05 08:04:00-04:00,VRTX,neutral
1327646.0,"Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences",2013-03-28 08:18:00-04:00,VRTX,negative
1327647.0,Moving Averages Indicate These Sector ETFs Could be Stretched,2013-03-25 17:33:00-04:00,VRTX,neutral
1327648.0,Stocks to Watch Next Week,2013-03-25 10:42:00-04:00,VRTX,neutral
1327649.0,Friday March 22th Watchlist,2013-03-22 08:42:00-04:00,VRTX,neutral
1327650.0,UPDATE: JP Morgan Raises PT on Vertex Pharmaceuticals on Phase 3 Trials,2013-03-19 10:00:00-04:00,VRTX,positive
1327651.0,"JP Morgan Maintains Overweight on Vertex Pharmaceuticals Incorporated, Raises PT to $86.00",2013-03-19 08:29:00-04:00,VRTX,neutral
1327652.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,VRTX,positive
1327653.0,Summer Street Says Fast Track Unlikely for Sarepta's Eteplirsen,2013-03-05 12:26:00-05:00,VRTX,neutral
1327654.0,"Vertex Announces VX-787 Showed Significant Antiviral Activity, Reduced Severity, Duration of Flu Systems in Phase 2 Study, Met Primary Endpoint",2013-03-04 08:35:00-05:00,VRTX,negative
1327655.0,Vertex Pharma Files Automatic Mixed Securities Shelf,2013-03-01 16:05:00-05:00,VRTX,positive
1327656.0,"Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)",2013-02-28 15:13:00-05:00,VRTX,positive
1327657.0,Vertex Pharma Announces Initiation of Pivotal Phase 3 Program of VX-809,2013-02-26 16:23:00-05:00,VRTX,neutral
1327658.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,VRTX,positive
1327659.0,Ireland Approves Funding for KALYDECO for Treatment of G551D,2013-02-01 12:39:00-05:00,VRTX,positive
1327660.0,Kalydeco Approved in Irleand for Cystic Fibrosis Patients,2013-02-01 11:24:00-05:00,VRTX,positive
1327661.0,Vertex Pharmaceuticals Incorporated Sees FY2013 Sales $1.10B-1.25B vs $1.13B Est,2013-01-29 16:24:00-05:00,VRTX,neutral
1327662.0,"Vertex Pharmaceuticals Reports Q4 Non-GAAP EPS of $0.04 Excluding Items, Revenue of $334 Million vs $318.1 Million Est.",2013-01-29 16:03:00-05:00,VRTX,neutral
1327663.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,VRTX,positive
1327664.0,Vertex Pharma Shares Sink on Lazard Downgrade,2013-01-15 09:41:00-05:00,VRTX,positive
1327665.0,"Vertex Pharma CEO Says Co. to Focus on Developing Specialty Diseases, Seeking a Partner for Rheumatoid Arthritis Compound",2013-01-09 08:22:00-05:00,VRTX,neutral
1327666.0,"Janney Capital Initiates Coverage on Vertex Pharmaceuticals Incorporated at Buy, Announces $54.00 PT",2013-01-02 17:10:00-05:00,VRTX,neutral
1327667.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,VRTX,positive
1327668.0,Vertex Pharma Reports Update to US Prescribing Info for INCIVEK,2012-12-19 08:34:00-05:00,VRTX,neutral
1327669.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,VRTX,positive
1327670.0,"UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Vertex Pharmaceuticals",2012-12-07 09:35:00-05:00,VRTX,negative
1327671.0,"Deutsche Bank Maintains Buy on Vertex Pharmaceuticals Incorporated, Lowers PT to $75.00",2012-12-07 08:26:00-05:00,VRTX,negative
1327672.0,Vertex Says Health Canada Approves KALYDECO,2012-12-03 08:33:00-05:00,VRTX,positive
1327673.0,"BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November",2012-12-02 20:29:00-05:00,VRTX,positive
1327674.0,"RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November",2012-12-01 13:38:00-05:00,VRTX,positive
1327675.0,"Benzinga's M&A Chatter for Wednesday November 28, 2012",2012-11-28 17:36:00-05:00,VRTX,neutral
1327676.0,UPDATE: Hearing Chatter Vertex May Buy North American Rights from Saretpa -Adam F Tweet,2012-11-28 11:20:00-05:00,VRTX,neutral
1327677.0,Hearing Unconfirmed Takeover Chatter in Sarepta,2012-11-28 11:15:00-05:00,VRTX,negative
1327678.0,Argus Research Downgrades Vertex Pharmaceuticals from Buy to Hold,2012-11-28 07:43:00-05:00,VRTX,neutral
1327679.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,VRTX,positive
1327680.0,UPDATE: Credit Suisse Downgrades Vertex Pharmaceuticals to Neutral on Competitive Pressures  ,2012-11-12 08:24:00-05:00,VRTX,positive
1327681.0,"Credit Suisse Downgrades Vertex Pharmaceuticals from Outperform to Neutral, Lowers PT from $56 to $48",2012-11-12 07:20:00-05:00,VRTX,positive
1327682.0,"Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)",2012-11-03 10:07:00-04:00,VRTX,positive
1327683.0,Benzinga Mid-Morning Market Update,2012-11-02 10:54:00-04:00,VRTX,neutral
1327684.0,UPDATE: Goldman Sachs Downgrades Vertex Pharmaceuticals to Sell on CF Combo Outlook  ,2012-11-02 08:07:00-04:00,VRTX,neutral
1327685.0,"Credit Suisse Maintains Vertex Pharmaceuticals at Outperform, Lowers PT from $58 to $56",2012-11-02 07:53:00-04:00,VRTX,positive
1327686.0,"Goldman Sachs Downgrades Vertex Pharmaceuticals from Neutral to Sell, Lowers PT from $55 to $43",2012-11-02 05:53:00-04:00,VRTX,negative
1327687.0,UPDATE: Vertex Pharmaceuticals Reports Q3 EPS $-0.27 vs $0.20 Est; Revenues $336M vs $377.14M Est,2012-11-01 16:42:00-04:00,VRTX,neutral
1327688.0,Vertex Pharmaceuticals Reports Q3 EPS $0.13 vs $0.20 Est; Revenues $336M vs $377.14M Est,2012-11-01 16:10:00-04:00,VRTX,neutral
1327689.0,"Vertex, JNJ's Janssen Enter Agreement for Phase 2 Hepatitis C Study",2012-11-01 07:39:00-04:00,VRTX,positive
1327690.0,"Vertex,  GlaxoSmithKline Enter Agreement for Phase 2 Hepatitis C Study",2012-11-01 07:36:00-04:00,VRTX,positive
1327691.0,Earnings Preview: Vertex Pharmaceuticals,2012-10-29 08:18:00-04:00,VRTX,neutral
1327692.0,"Earnings Scheduled For October 29, 2012",2012-10-29 07:01:00-04:00,VRTX,neutral
1327693.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,VRTX,positive
1327694.0,"Adam Feuerstein Says Sarepta Takeover Target, Possibly by Vertex",2012-10-23 09:47:00-04:00,VRTX,neutral
1327695.0,Vertex Spikes to Lows,2012-10-22 12:30:00-04:00,VRTX,negative
1327696.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)",2012-10-15 06:59:00-04:00,VRTX,positive
1327697.0,Adam Feuerstein Gets Positive Comments on Vertex VX809/Kalydeco Data ,2012-10-11 12:29:00-04:00,VRTX,positive
1327698.0,Vertex Says Did Not See Significant Difference in Weight Gain,2012-10-11 11:51:00-04:00,VRTX,positive
1327699.0,Vertex Pharmaceuticals Spikes Lower,2012-10-11 11:46:00-04:00,VRTX,negative
1327700.0,Vertex Pharmaceuticals Spikes Higher on Release of Positive Data,2012-10-11 11:43:00-04:00,VRTX,positive
1327701.0,Vertex Says Data from Phase 2 VX-809 Study Supports Plan for Program in Early 2013,2012-10-11 08:34:00-04:00,VRTX,positive
1327702.0,UPDATE: Deutsche Bank Initiates Vertex Pharmaceuticals at Buy on Cystic Fibrosis Outlook  ,2012-10-09 13:17:00-04:00,VRTX,neutral
1327703.0,"Deutsche Bank Initiates Coverage on Vertex Pharmaceuticals at Buy, Announces PT of $77",2012-10-09 05:55:00-04:00,VRTX,neutral
1327704.0,"Argus Initiates Coverage Vertex Pharmaceuticals at Buy, Announces PT of $68",2012-10-04 13:34:00-04:00,VRTX,neutral
1327705.0,Vertex Pharma Reports Presentation of New Data from Hepatitis C,2012-10-01 10:53:00-04:00,VRTX,neutral
1327706.0,Alios Biopharma Says Compounds Result in Potent Antiviral Activity; Sees Clinical Trial in 2013,2012-10-01 08:17:00-04:00,VRTX,neutral
1327707.0,Vertex Pharma Says AL-2158 Development Discontinued on Lack of Efficacy,2012-09-25 08:32:00-04:00,VRTX,negative
1327708.0,Yuchun Lee Appointed to the Vertex Board of Directors  ,2012-09-18 08:32:00-04:00,VRTX,neutral
1327709.0,Vertex Announces Appointment of Stuart A. Arbuckle as CCO,2012-09-04 08:33:00-04:00,VRTX,neutral
1327710.0,Short Interest in Biotech Firms on the Rise,2012-08-27 15:21:00-04:00,VRTX,positive
1327711.0,Bristol-Myers' Trash is Gilead Sciences' Treasure,2012-08-24 09:16:00-04:00,VRTX,positive
1327712.0,Idenix Shares Plunge After Hepatitis Drug Study Put on Hold ,2012-08-17 09:43:00-04:00,VRTX,positive
1327713.0,Vertex Pharmaceuticals Spokesperson Says No News to Account for Tuesday's Move,2012-08-14 12:03:00-04:00,VRTX,negative
1327714.0,Vertex Pharmaceuticals Spikes Higher,2012-08-14 11:52:00-04:00,VRTX,neutral
1327715.0,"UBS Maintains Vertex Pharmaceuticals at Buy, Lowers PT from $63 to $60",2012-07-31 12:36:00-04:00,VRTX,negative
1327716.0,UPDATE: Bank of America Lowers Price Target on Vertex Pharmaceuticals from $71 to $66,2012-07-31 09:43:00-04:00,VRTX,negative
1327717.0,"Citigroup Maintains Vertex Pharmaceuticals at Buy, Lowers PT from $66 to $63",2012-07-31 07:50:00-04:00,VRTX,negative
1327718.0,"Bank of America Maintains Vertex Pharmaceuticals at Buy, Lowers PT from $71 to $66",2012-07-31 07:21:00-04:00,VRTX,negative
1327719.0,Piper Jaffray Downgrades Vertex Pharmaceuticals from Overweight to Neutral,2012-07-31 06:49:00-04:00,VRTX,negative
1327720.0,"Goldman Sachs Maintains Vertex Pharmaceuticals at Neutral, Lowers PT from $60 to $55",2012-07-31 06:39:00-04:00,VRTX,negative
1327721.0,Vertex Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis ,2012-07-30 16:11:00-04:00,VRTX,positive
1327722.0,Vertex Pharmaceuticals Reports Q2 EPS $0.46 vs $0.59 Est; Revenues $418.3M vs $472.16M Est,2012-07-30 16:04:00-04:00,VRTX,neutral
1327723.0,"Benzinga Market Primer, Monday July 30",2012-07-30 07:07:00-04:00,VRTX,neutral
1327724.0,Possible Hepatitis C Outbreak Could Lift This ETF,2012-07-30 06:53:00-04:00,VRTX,neutral
1327725.0,European Commission Approves Vertex Drug Kalydeco Ahead of Monday Earnings -IBD,2012-07-27 13:15:00-04:00,VRTX,positive
1327726.0,"Dendreon, Pharmacyclics and Other Biotech Takeover Targets",2012-07-10 14:07:00-04:00,VRTX,neutral
1327727.0,"S&P: Not All Mid-Cap ETFs Created Equal (MDY, VO)",2012-07-05 14:37:00-04:00,VRTX,positive
1327728.0,Vertex Pharmaceuticals Falls 20% on JP Morgan Report,2012-06-28 15:12:00-04:00,VRTX,positive
1327729.0,JP Morgan Buyer on Vertex Pharmaceuticals' Weakness,2012-06-28 10:45:00-04:00,VRTX,negative
1327730.0,"Social Media Outlook for Thursday June 28 (ENOC, ENTR, JPM, VRTX)",2012-06-28 10:17:00-04:00,VRTX,neutral
1327731.0,"Financial Breakfast: Morning News Summary for June 28, 2012",2012-06-28 07:37:00-04:00,VRTX,neutral
1327732.0,Vertex Announces Final Data from Phase 2 Combination Study of VX-809 and KALYDECO (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  ,2012-06-28 07:16:00-04:00,VRTX,positive
1327733.0,Long Options to Take Profits (Without Selling Stock),2012-06-26 11:33:00-04:00,VRTX,positive
1327734.0,"Option Alert: Vertex Pharmaceuticals July 70 Call; Block Trade: 3,600 Contracts; Currently $58.47",2012-06-19 11:38:00-04:00,VRTX,negative
1327735.0,Vertex Studying Drug Combination for Cystic Fibrosis -Bloomberg,2012-06-07 15:13:00-04:00,VRTX,neutral
1327736.0,Senator Charles Grassley Calls on SEC to Investigate Vertex,2012-06-07 13:30:00-04:00,VRTX,neutral
1327737.0,UPDATE: Vertex Says Kalydeco for Treatment of Cystic Fibrosis,2012-06-07 13:18:00-04:00,VRTX,neutral
1327738.0,"Vertex Pharma Says Kalydeco Showed Lung Function Improvement, Improvements Durable Up to 96 Weeks",2012-06-07 13:16:00-04:00,VRTX,positive
1327739.0,Vertex Pharmaceuticals Spiking Lower,2012-06-07 13:15:00-04:00,VRTX,negative
1327740.0,"Survive The Summer With These ETFs (PEJ, NUGT, FBT)",2012-06-05 12:27:00-04:00,VRTX,neutral
1327741.0,FDA Issues Warning Letter on Vertex Incivek,2012-05-30 13:02:00-04:00,VRTX,negative
1327742.0,Morgan Stanley Lowers PT on Vertex Pharmaceuticals After Corrected CF Data,2012-05-29 14:17:00-04:00,VRTX,negative
1327743.0,Vertex Pharmaceuticals Trading 12.1% Lower on Heavy Volume; Currently at $57.03,2012-05-29 12:56:00-04:00,VRTX,negative
1327744.0,Vertex Pharmaceuticals Down 17% After Revising Study Results ,2012-05-29 11:05:00-04:00,VRTX,neutral
1327745.0,"Social Media Outlook for Tuesday May 29 (BID, IBM, VRTX, MSFT)",2012-05-29 10:57:00-04:00,VRTX,neutral
1327746.0,JP Morgan Reiterates Overweight on Vertex Pharmaceuticals on Continued Share Upside Amid Weakness  ,2012-05-29 09:42:00-04:00,VRTX,negative
1327747.0,Vertex Says Conclusions and Plans Haven't Changed with New Data; High Dose of CF Drug Showed Most Robust Results,2012-05-29 09:07:00-04:00,VRTX,positive
1327748.0,Benzinga's Top Pre-Market Losers,2012-05-29 08:19:00-04:00,VRTX,negative
1327749.0,Vertex Pharmaceuticals Falls 25% Pre-Market on Revised Phase 2 Data,2012-05-29 07:42:00-04:00,VRTX,neutral
1327750.0,Vertex Pharmaceuticals Falls 15% Pre-Market on Corrected Phase 2 Data,2012-05-29 07:21:00-04:00,VRTX,neutral
1327751.0,Vertex Pharmaceuticals Resumes Trading,2012-05-29 07:20:00-04:00,VRTX,neutral
1327752.0,PREVIEW: Vertex Pharmaceuticals to Resume Trading at 7:20am,2012-05-29 07:08:00-04:00,VRTX,neutral
1327753.0,Vertex Pharmaceuticals Halted; Pending News,2012-05-29 07:01:00-04:00,VRTX,neutral
1327754.0,Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation   ,2012-05-29 07:01:00-04:00,VRTX,neutral
1327755.0,"Vertex Receives European CHMP Positive Opinion for KALYDECO (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis   ",2012-05-25 07:52:00-04:00,VRTX,positive
1327756.0,Vertex Appoints David Altshuler to its Board of Directors   ,2012-05-24 09:02:00-04:00,VRTX,neutral
1327757.0,"The Definitive Biotech ETF Guide (IBB, XBI, FBT)",2012-05-21 13:35:00-04:00,VRTX,neutral
1327758.0,"S&P Bullish On Biotech ETFs (FBT, IBB, XBI)",2012-05-15 14:31:00-04:00,VRTX,neutral
1327759.0,"Benzinga's Top Upgrades with Color for May 14, 2012",2012-05-14 12:52:00-04:00,VRTX,positive
1327760.0,UPDATE: J.P. Morgan Upgrades Vertex Pharmaceuticals; Raises PT,2012-05-14 07:53:00-04:00,VRTX,neutral
1327761.0,"JP Morgan Upgrades Vertex Pharmaceuticals from Neutral to Overweight, Raises PT from $45 to $82",2012-05-14 05:55:00-04:00,VRTX,neutral
1327762.0,"UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT for Vertex Pharmaceuticals",2012-05-11 11:11:00-04:00,VRTX,neutral
1327763.0,"Goldman Sachs Maintains Vertex Pharmaceuticals at Neutral, Raises PT from $40 to $60",2012-05-11 07:06:00-04:00,VRTX,neutral
1327764.0,"Benzinga's Top Upgrades with Color for May 8, 2012",2012-05-08 12:08:00-04:00,VRTX,positive
1327765.0,"Social Media Outlook for Tuesday May 8 (LPX, DTV, MAKO, FOSL)",2012-05-08 10:34:00-04:00,VRTX,neutral
1327766.0,UPDATE: Brean Murray Carret & Co. Upgrades Vertex Pharmaceuticals,2012-05-08 07:57:00-04:00,VRTX,neutral
1327767.0,"Financial Breakfast: Morning News Summary for May 8, 2012",2012-05-08 07:29:00-04:00,VRTX,neutral
1327768.0,UPDATE: Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-Weight; Interim CF Data  ,2012-05-08 07:07:00-04:00,VRTX,neutral
1327769.0,"Morgan Stanley Upgrades Vertex Pharmaceuticals from Underweight to Equal-weight, Raises PT from $28 to $51",2012-05-08 06:29:00-04:00,VRTX,neutral
1327770.0,"Brean Murray Carret & Co. Upgrades Vertex Pharmaceuticals from Hold to Buy, Announces PT of $69",2012-05-08 06:25:00-04:00,VRTX,neutral
1327771.0,Vertex Pharmaceuticals Trading 52.8% Higher on Heavy Volume; Currently at $57.16,2012-05-07 14:31:00-04:00,VRTX,neutral
1327772.0,Vertex Pharmaceuticals Soars on Promising Drug Data,2012-05-07 12:52:00-04:00,VRTX,positive
1327773.0,Vertex Pharma Stock Jumps on Cystic Fibrosis Data - IBD,2012-05-07 11:30:00-04:00,VRTX,neutral
1327774.0,Piper Jaffray Raises Vertex Pharmaceuticals Price Target from $56 to $75 ,2012-05-07 11:13:00-04:00,VRTX,neutral
1327775.0,J.P. Morgan Reiterates Neutral Rating for Vertex Pharmaceuticals,2012-05-07 10:30:00-04:00,VRTX,neutral
1327776.0,"Social Media Outlook for Monday May 7 (VRTX, TSN, AIG, MSFT)",2012-05-07 10:00:00-04:00,VRTX,neutral
1327777.0,"Benzinga's Top Upgrades with Color for May 7, 2012",2012-05-07 09:51:00-04:00,VRTX,positive
1327778.0, UPDATE: ISI Group Upgrades Vertex Pharmaceuticals ,2012-05-07 09:24:00-04:00,VRTX,neutral
1327779.0,Vertex Pharmaceuticals Pops 60% on Positive Phase 2 Study,2012-05-07 08:40:00-04:00,VRTX,positive
1327780.0,"ISI Group Upgrades Vertex Pharmaceuticals from Neutral to Buy, Announces PT of $68",2012-05-07 08:37:00-04:00,VRTX,neutral
1327781.0,Vertex Pharmaceuticals Resumes Trading,2012-05-07 07:50:00-04:00,VRTX,neutral
1327782.0,Vertex Announces Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO Showed Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,2012-05-07 07:29:00-04:00,VRTX,positive
1327783.0,Vertex Pharmaceuticals Halted for Pending News ,2012-05-07 07:27:00-04:00,VRTX,neutral
1327784.0,Vertex Pharmaceuticals Reports Q1 EPS $0.55 vs $0.57 Est; Revenues $438.7M vs $452.29M Est,2012-04-26 16:26:00-04:00,VRTX,neutral
1327785.0,Vertex Advances INCIVEK and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C   ,2012-04-18 16:00:00-04:00,VRTX,positive
1327786.0,"Option Alert: Vertex Pharmaceuticals May 38 Call; Block Trade, 2,250 Contracts",2012-04-17 12:39:00-04:00,VRTX,negative
1327787.0,"UBS Maintains Vertex Pharmaceuticals at Neutral, Lowers PT from $44 to $41",2012-04-13 09:55:00-04:00,VRTX,negative
1327788.0,"UBS Maintains Vertex Pharmaceuticals at Neutral, Raises PT from $35 to $44",2012-03-28 11:30:00-04:00,VRTX,neutral
1327789.0,Benzinga's Top Downgrades,2012-03-19 07:35:00-04:00,VRTX,positive
1327790.0,"Financial Breakfast: Morning News Summary for March 19, 2012",2012-03-19 07:22:00-04:00,VRTX,neutral
1327791.0,UPDATE: Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight,2012-03-19 06:35:00-04:00,VRTX,neutral
1327792.0,"Morgan Stanley Downgrades Vertex Pharmaceuticals from Equal-weight to Underweight, Maintains PT at $30",2012-03-19 06:01:00-04:00,VRTX,neutral
1327793.0,"Bank of America Maintains Vertex Pharmaceuticals at Buy, Raises PO from $41 to $49",2012-03-14 08:33:00-04:00,VRTX,negative
1327794.0,"Hearing Summer Street Positive on Vertex Pharmaceuticals, PT $57",2012-03-09 10:00:00-05:00,VRTX,positive
1327795.0,Data from Phase 2 Study of an INCIVEK Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)   ,2012-03-06 11:00:00-05:00,VRTX,neutral
1327796.0,Vertex Pharmaceuticals Trading 1.5% Higher on Heavy Volume; Currently at $38.84,2012-02-29 09:55:00-05:00,VRTX,neutral
1327797.0,"Benzinga's M&A Chatter for Monday February 27, 2012",2012-02-27 17:37:00-05:00,VRTX,neutral
1327798.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-02-27 10:16:00-05:00,VRTX,positive
1327799.0,"Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C   ",2012-02-23 08:32:00-05:00,VRTX,neutral
1327800.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2012-02-21 03:00:00-05:00,VRTX,negative
1327801.0,Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish,2012-02-17 12:30:00-05:00,VRTX,negative
1327802.0,"Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix",2012-02-17 07:54:00-05:00,VRTX,negative
1327803.0,Vertex Pharmaceuticals Seeing Strength this Morning after Gilead's Negative Results,2012-02-17 07:37:00-05:00,VRTX,negative
1327804.0,"Vertex Pharmaceuticals Rises 9% Pre-Market, $41.01",2012-02-17 07:37:00-05:00,VRTX,neutral
1327805.0,"Benzinga's M&A Chatter for Tuesday February 14, 2012",2012-02-14 18:32:00-05:00,VRTX,neutral
1327806.0,Hearing Renewed Takeover Chatter in Vertex Pharmaceuticals,2012-02-14 09:56:00-05:00,VRTX,neutral
1327807.0,"Benzinga's M&A Chatter for Wednesday February 8, 2012",2012-02-08 19:59:00-05:00,VRTX,neutral
1327808.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-02-08 11:40:00-05:00,VRTX,positive
1327809.0,Hearing Takeover Chatter in Vertex,2012-02-08 11:40:00-05:00,VRTX,neutral
1327810.0,Vertex Pharma Down 5% After INCIVEK sales disappoint.,2012-02-03 13:36:00-05:00,VRTX,negative
1327811.0,UPDATE: Goldman Sachs Downgrades Vertex Pharmaceuticals to Neutral,2012-02-03 08:58:00-05:00,VRTX,neutral
1327812.0,Benzinga's Top Downgrades,2012-02-03 07:23:00-05:00,VRTX,positive
1327813.0,Goldman Sachs Downgrades Vertex Pharma to Neutral,2012-02-03 06:05:00-05:00,VRTX,neutral
1327814.0,"Benzinga's M&A Chatter for Thursday February 2, 2012",2012-02-02 19:57:00-05:00,VRTX,neutral
1327815.0,Vertex Pharmaceuticals Reports Q4 EPS $0.86 vs $0.70 Est; Revenues $563.30M vs $518.36M Est	 		,2012-02-02 16:04:00-05:00,VRTX,neutral
1327816.0,Achillion Pharmaceuticals Spokesperson Would Not Comment on Rumor of Vertex Offer,2012-02-02 10:11:00-05:00,VRTX,neutral
1327817.0,"Hearing Achillion Pharmaceuticals Accepted $19.75 Offer From Vertex, Not Confirmed",2012-02-02 10:03:00-05:00,VRTX,positive
1327818.0,Positive Rumors Circulate About Achillion Pharmaceuticals,2012-02-02 10:03:00-05:00,VRTX,positive
1327819.0, Vertex Pharmaceutical Resumes Trading,2012-01-31 13:35:00-05:00,VRTX,neutral
1327820.0,PREVIEW: Vertex Pharma to Resume Trading 1:35 p.m.,2012-01-31 13:33:00-05:00,VRTX,neutral
1327821.0,Vertex Pharma Surging on FDA Approval,2012-01-31 13:07:00-05:00,VRTX,positive
1327822.0,Vertex Pharmaceutical Says Could See European Approval for Kalydeco in Q3 -Reuters ,2012-01-31 12:56:00-05:00,VRTX,positive
1327823.0,Vertex Pharmaceuticals Halted for News Pending,2012-01-31 11:27:00-05:00,VRTX,neutral
1327824.0,"UPDATE: Vertex Pharmaceuticals Confirms FDA Approves KALYDECO, the First Medicine to Treat the Underlying Cause of Cystic Fibrosis   ",2012-01-31 11:25:00-05:00,VRTX,positive
1327825.0,Vertex Pharmaceuticals Trading 9.7% Higher on Heavy Volume; Currently at $38.11,2012-01-31 11:24:00-05:00,VRTX,neutral
1327826.0,Vertex Pharmaceuticals Trading 7.8% Higher on FDA Approval,2012-01-31 11:06:00-05:00,VRTX,positive
1327827.0,FDA Approves Vertex's Kalydeco for Cystic Fibrosis,2012-01-31 11:04:00-05:00,VRTX,positive
1327828.0,Vertex Pharmaceuticals Trading 3.8% Higher on Heavy Volume; Currently at $36.05,2012-01-31 11:03:00-05:00,VRTX,neutral
1327829.0,"Benzinga's M&A Chatter for Tuesday January 24, 2012",2012-01-24 18:53:00-05:00,VRTX,neutral
1327830.0,Achillion Pharmaceuticals Spiking Higher on Renewed Takeover Chatter,2012-01-24 09:49:00-05:00,VRTX,neutral
1327831.0,"Benzinga's M&A Chatter for Wednesday January 18, 2012",2012-01-18 18:53:00-05:00,VRTX,neutral
1327832.0,Positive Rumors Circulate About Vertex Pharmaceuticals,2012-01-18 09:43:00-05:00,VRTX,positive
1327833.0,Hearing Takeover Chatter in Vertex,2012-01-18 09:43:00-05:00,VRTX,neutral
1327834.0,Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?,2012-01-10 14:54:00-05:00,VRTX,neutral
1327835.0,A Peek Into The Market Before The Trading Starts,2012-01-09 07:28:00-05:00,VRTX,neutral
1327836.0,Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis  ,2012-01-09 06:56:00-05:00,VRTX,neutral
1327837.0,Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis,2012-01-08 20:32:00-05:00,VRTX,neutral
1327838.0,"Piper Jaffray Reiterates Overweight, $56 PT On Vertex",2012-01-03 11:23:00-05:00,VRTX,negative
1327839.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,VRTX,positive
1327840.0,RBC Capital Upgrades Vertex Pharmaceuticals to Top Pick,2011-12-19 07:16:00-05:00,VRTX,positive
1327841.0,"Benzinga's M&A Chatter for Thursday December 15, 2011",2011-12-15 17:47:00-05:00,VRTX,neutral
1327842.0,FDA Grants Priority Review for KALYDECO,2011-12-15 07:46:00-05:00,VRTX,positive
1327843.0,Vertex Announces CEO Succession Plan; Jeffrey Leiden to become CEO in February 2012 ,2011-12-15 07:45:00-05:00,VRTX,positive
1327844.0,Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C  ,2011-12-09 08:38:00-05:00,VRTX,neutral
1327845.0,"Citi Reiterates Buy, $42 PT On Vertex",2011-12-05 12:53:00-05:00,VRTX,neutral
1327846.0,"Piper Jaffray Maintains Overweight, $56 Target on Vertex Pharmaceuticals ",2011-12-05 06:53:00-05:00,VRTX,negative
1327847.0,"Mad Money Lightning Round: Cramer Dislikes Microsoft, Radioshack",2011-12-01 05:52:00-05:00,VRTX,negative
1327848.0,"Investor Ideas' Biotech and Pharma Stock Investor Alert for Aethlon Medical, Vertex, Pharmasset",2011-11-28 11:21:00-05:00,VRTX,positive
1327849.0,Citi Maintains Buy Rating and $59 PT on Vertex Pharmaceuticals ,2011-11-28 09:20:00-05:00,VRTX,neutral
1327850.0,Investor Ideas' Hepatitis C Virus (HCV) Biotech and Pharma Stock Investor Alert,2011-11-25 12:30:00-05:00,VRTX,positive
1327851.0,Vertex Pharmaceuticals Hits 52-Week Low of $26.74,2011-11-25 09:31:00-05:00,VRTX,negative
1327852.0,Vertex Pharmaceuticals Hits 52-Week Low of $27.33,2011-11-23 10:18:00-05:00,VRTX,negative
1327853.0,Vertex Pharmaceuticals Hits 52-Week Low of $27.36,2011-11-22 09:34:00-05:00,VRTX,negative
1327854.0,Hep-C Stocks Soar On M&A News,2011-11-21 13:14:00-05:00,VRTX,neutral
1327855.0,GILD Acquires VRUS,2011-11-21 11:00:00-05:00,VRTX,neutral
1327856.0,Vertex Pharmaceuticals Hits 52-Week Low of $27.49,2011-11-21 09:53:00-05:00,VRTX,negative
1327857.0,Vertex Pharmaceuticals hits 52-Week low,2011-11-18 09:31:00-05:00,VRTX,negative
1327858.0,VRTX hits 52-Week low,2011-11-17 09:30:00-05:00,VRTX,negative
1327859.0,VRTX hits 52-Week low,2011-11-16 15:35:00-05:00,VRTX,negative
1327860.0,Bank of America Maintains PO on Vertex Pharmaceuticals Ahead of Fork in the Road,2011-11-10 07:48:00-05:00,VRTX,negative
1327861.0,Morgan Stanley Upgrading Vertex Pharmaceuticals,2011-11-10 07:41:00-05:00,VRTX,neutral
1327862.0,"Financial Breakfast: Morning News Summary for November 10, 2011",2011-11-10 07:40:00-05:00,VRTX,neutral
1327863.0,"Morgan Stanley Upgrades Vertex Pharmaceuticals to Equal-weight, $32 PT",2011-11-10 06:18:00-05:00,VRTX,neutral
1327864.0,"Vertex Pharmaceuticals Hits New 52-Week Low, $31.47",2011-11-08 09:32:00-05:00,VRTX,negative
1327865.0,UPDATE: Piper Jaffray Lowers Price Target on Vertex to $56,2011-11-08 08:30:00-05:00,VRTX,negative
1327866.0,Piper Jaffray Lowers PT on Vertex Pharmaceuticals to $56,2011-11-08 07:34:00-05:00,VRTX,negative
1327867.0,Benzinga's Top Downgrades,2011-11-08 07:20:00-05:00,VRTX,positive
1327868.0,"Afternoon Movers; DreamWorks Moves Up on Positive ""Puss in Boots"" Sales",2011-11-07 16:36:00-05:00,VRTX,positive
1327869.0,Benzinga's Top Pre-Market Losers,2011-11-07 08:16:00-05:00,VRTX,negative
1327870.0,Vertex Pharmaceuticals Announces Positive Interim Data From a Phase 2 Study of INCIVEK,2011-11-05 14:47:00-04:00,VRTX,positive
1327871.0,Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C   ,2011-11-04 09:01:00-04:00,VRTX,positive
1327872.0,Vertex Pharmaceuticals Announces Phase 3 Study of KALYDECO in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks   ,2011-11-03 09:35:00-04:00,VRTX,positive
1327873.0,Vertex Pharmaceuticals Incorporated's Earnings Report,2011-10-27 18:09:00-04:00,VRTX,neutral
1327874.0,Vertex Pharmaceuticals Reports Q3 Revenues $659.2M May Not Compare vs $343.42M Est		,2011-10-27 16:11:00-04:00,VRTX,neutral
1327875.0,Vertex Provides Updates on INCIVEKTM Launch and Medicines in Development  ,2011-10-27 16:09:00-04:00,VRTX,neutral
1327876.0,"Earnings Preview: Vertex Pharmaceuticals' EPS, Revenue Expected to Rise",2011-10-25 13:50:00-04:00,VRTX,neutral
1327877.0,Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure with a Total Treatment Duration of 12 Weeks of INCIVEK Combination Therapy  ,2011-10-24 16:34:00-04:00,VRTX,neutral
1327878.0,Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology  ,2011-10-24 16:02:00-04:00,VRTX,negative
1327879.0,Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C ,2011-10-24 08:35:00-04:00,VRTX,neutral
1327880.0,Vertex Submits Application for Priority Review and Approval of KALYDECO in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis   ,2011-10-19 08:04:00-04:00,VRTX,positive
1327881.0,Benzinga's Volume Movers,2011-10-13 10:42:00-04:00,VRTX,neutral
1327882.0,Piper Jaffray Maintains Overweight Rating and $63 PT on Vertex Pharmaceuticals,2011-10-12 08:18:00-04:00,VRTX,negative
1327883.0,Vertex Pharma Spiking Lower on Heavy Volume,2011-10-11 14:21:00-04:00,VRTX,negative
1327884.0,Bank of America Lowers PO on Vertex Pharmaceuticals to $55,2011-10-11 10:27:00-04:00,VRTX,negative
1327885.0,Vertex Pharmaceuticals' INCIVEK Now Available in Canada for People with Hepatitis C   ,2011-10-11 08:01:00-04:00,VRTX,neutral
1327886.0,Some Stocks Are Just To Weak To Participate,2011-10-10 15:53:00-04:00,VRTX,negative
1327887.0,Midday Losers; Vertex Pharmaceuticals Down 9%,2011-10-10 13:33:00-04:00,VRTX,negative
1327888.0,Keep These Stocks On The Radar,2011-10-04 11:02:00-04:00,VRTX,neutral
1327889.0,Citi Maintains Buy on Vertex Pharmaceuticals,2011-10-03 08:50:00-04:00,VRTX,neutral
1327890.0,Hearing Citigroup Making Cautious Comments on Vertex Pharma,2011-09-27 12:42:00-04:00,VRTX,negative
1327891.0,Citi Has Buy On Vertex Pharmaceuticals ,2011-09-06 09:03:00-04:00,VRTX,neutral
1327892.0,A Peek Into The Market Before The Trading Starts,2011-09-06 08:14:00-04:00,VRTX,neutral
1327893.0,Vertex Pharmaceuticals Announces Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis   ,2011-09-06 07:32:00-04:00,VRTX,positive
1327894.0,Health Canada Approves INCIVEK(TM) (telaprevir) for People With Hepatitis C,2011-08-22 07:31:00-04:00,VRTX,positive
1327895.0,UPDATE: Citadel Securities Initiates Coverage on Vertex,2011-08-08 07:04:00-04:00,VRTX,positive
1327896.0,"Citadel Initiates Vertex Pharmaceuticals At Neutral, $46 PT",2011-08-08 06:07:00-04:00,VRTX,neutral
1327897.0,Vertex Pharmaceuticals Narrows Loss,2011-07-28 17:25:00-04:00,VRTX,negative
1327898.0,Vertex Pharma Reports Q2 Revenues $114.4M	,2011-07-28 16:38:00-04:00,VRTX,neutral
1327899.0,Interim Data from Phase 2 Study of Combination Regimen Including VX-222,2011-07-26 07:36:00-04:00,VRTX,neutral
1327900.0,Vertex Reports First data from Phase 2 Study of Combination Regimen Showing Potential for Viral Cure in Many Patients with a 12-week Combination Regimen of Multiple Direct-Acting Antivirals  ,2011-07-26 07:36:00-04:00,VRTX,neutral
1327901.0,"Vertex Pharmaceuticals Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter",2011-07-25 13:49:00-04:00,VRTX,negative
1327902.0,Goldman Sachs Provides Color on Biotechnology,2011-07-13 08:18:00-04:00,VRTX,neutral
1327903.0,Piper Jaffray Reiterates Overweight and PT of $63 on Vertex Pharmaceuticals ,2011-07-12 09:06:00-04:00,VRTX,negative
1327904.0,"Street Overestimating Sales of Vertex's Incivek, Morgan Stanley Reports",2011-06-23 07:35:00-04:00,VRTX,neutral
1327905.0,Morgan Stanley Lowers PT On Vertex Pharmaceuticals To $32,2011-06-23 06:26:00-04:00,VRTX,negative
1327906.0,Vertex Pharmaceuticals Announces New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK in Hepatitis C   ,2011-06-22 17:01:00-04:00,VRTX,neutral
1327907.0,J.P. Morgan Comments On Vertex Collaboration,2011-06-14 08:58:00-04:00,VRTX,neutral
1327908.0,Piper Jaffray Maintains Overweight on Vertex Pharmaceuticals,2011-06-13 07:23:00-04:00,VRTX,negative
1327909.0,Vertex Pharmaceuticals Announces Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis ,2011-06-10 11:01:00-04:00,VRTX,positive
1327910.0,Goldman Sachs Closes Out Two Losing Trades,2011-06-10 09:33:00-04:00,VRTX,negative
1327911.0,J.P. Morgan Gives Update On VRTX,2011-06-10 08:12:00-04:00,VRTX,neutral
1327912.0,Top Percentage Gainers and Losers as of 2pm 06/09/11,2011-06-09 14:02:00-04:00,VRTX,negative
1327913.0,Top Percentage Gainers and Losers as of 12pm 06/09/11,2011-06-09 12:04:00-04:00,VRTX,negative
1327914.0,"Vertex Extends Drop, Loses as Much as 12% in Active Trading ",2011-06-09 10:23:00-04:00,VRTX,negative
1327915.0,Benzinga's Top Pre-Market NASDAQ Losers,2011-06-09 08:23:00-04:00,VRTX,negative
1327916.0,A Peek Into The Market Before The Trading Starts,2011-06-09 07:32:00-04:00,VRTX,neutral
1327917.0,Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People ,2011-06-09 07:01:00-04:00,VRTX,positive
1327918.0,Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People ,2011-06-09 07:01:00-04:00,VRTX,positive
1327919.0,Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks,2011-06-03 11:35:00-04:00,VRTX,neutral
1327920.0,Morgan Stanley Reports Vertex Pharmaceuticals,2011-05-25 07:49:00-04:00,VRTX,neutral
1327921.0,UPDATE: J.P. Morgan Raises PT on Vertex Pharmaceuticals to $53,2011-05-24 07:33:00-04:00,VRTX,neutral
1327922.0,Bank Of America Comments On Vertex Pharmaceuticals FDA Approvals,2011-05-24 07:30:00-04:00,VRTX,neutral
1327923.0,JP Morgan Raises PT On Vertex Pharmaceuticals To $53,2011-05-24 06:22:00-04:00,VRTX,positive
1327924.0,"UPDATE: Vertex: Incivek Priced At $49,200 For 12 Weeks -Dow Jones",2011-05-23 11:32:00-04:00,VRTX,neutral
1327925.0,UPDATE: FDA approves Vertex Incivek for hepatitis C ,2011-05-23 09:40:00-04:00,VRTX,positive
1327926.0,Vertex Hepatitis C Drug Approved by the FDA -Bloomberg,2011-05-23 09:20:00-04:00,VRTX,positive
1327927.0,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,2011-05-18 06:29:00-04:00,VRTX,neutral
1327928.0,"Biotech/Pharma Stocks News Alert; Hepatitis C Virus (HCV) FDA News from Aethlon Medical, Vertex Pharmaceuticals, Merck & Company ",2011-05-17 11:46:00-04:00,VRTX,positive
1327929.0,"Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)",2011-05-17 09:00:00-04:00,VRTX,positive
1327930.0,"Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)",2011-05-17 09:00:00-04:00,VRTX,positive
1327931.0,Morgan Stanley Maintains Underweight on Vertex Pharmaceuticals (VRTX),2011-05-16 08:35:00-04:00,VRTX,neutral
1327932.0,J.P. Morgan Reiterates Neutral on Vertex Pharmaceuticals (VRTX),2011-05-16 07:43:00-04:00,VRTX,neutral
1327933.0,Piper Jaffray Reiterates Overweight on Vertex Pharmaceuticals (VRTX),2011-05-16 07:26:00-04:00,VRTX,negative
1327934.0,"Biotech/Pharma Stock News Alert: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 13:09:00-04:00,VRTX,positive
1327935.0,"Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 09:00:00-04:00,VRTX,positive
1327936.0,"Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)",2011-05-13 09:00:00-04:00,VRTX,positive
1327937.0,Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX),2011-05-11 09:22:00-04:00,VRTX,neutral
1327938.0,"Market updates- BG Group, Celanese, InterContinental Hotels, Imperial Tobacco, Schroders, CE, IHG, IMT, SDR, BG, VRTX, SLXP",2011-05-10 09:11:00-04:00,VRTX,neutral
1327939.0,Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX),2011-05-09 09:25:00-04:00,VRTX,neutral
1327940.0,"Vertex may be an Acquisition Target, Goldman Sachs Says -Bloomberg (VRTX, GS)",2011-05-09 07:20:00-04:00,VRTX,neutral
1327941.0,May Catalysts for Biotech and Drug Stocks,2011-05-04 12:32:00-04:00,VRTX,neutral
1327942.0,VRTX Revenue Above Goldman Sachs Estimate,2011-05-04 09:07:00-04:00,VRTX,neutral
1327943.0,"Benzinga's Top Downgrades (VRTX, DGI, KAR, CCC)",2011-05-04 08:17:00-04:00,VRTX,positive
1327944.0,J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX),2011-05-02 07:57:00-04:00,VRTX,neutral
1327945.0,FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C (VRTX),2011-04-28 16:22:00-04:00,VRTX,positive
1327946.0,FDA Panel Recommends Vertex's Telaprevir In 18-0 Vote -Bloomberg (VRTX),2011-04-28 15:13:00-04:00,VRTX,positive
1327947.0, Vertex Stock Booms After FDA Reports New Drug is Effective (VRTX),2011-04-26 14:00:00-04:00,VRTX,positive
1327948.0,Vertex Jumps Over 13% Higher After FDA Results (VRTX),2011-04-26 10:51:00-04:00,VRTX,neutral
1327949.0,Update: Vertex Hepatitis C Drug is Effective -Bloomberg (VRTX) ,2011-04-26 10:45:00-04:00,VRTX,positive
1327950.0,"Vertex Hepatitis C Drug Is Effective, FDA Reviewers Say -Bloomberg (VRTX)",2011-04-26 10:34:00-04:00,VRTX,positive
1327951.0,Citi Rates Vertex Pharmaceuticals High-Risk (VRTX),2011-04-07 09:06:00-04:00,VRTX,neutral
1327952.0,Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis   ,2011-04-07 08:08:00-04:00,VRTX,positive
1327953.0,April Catalysts For Biotech And Drug Stocks,2011-04-01 12:36:00-04:00,VRTX,neutral
1327954.0,Piper Jaffray Comments On Vertex Pharmaceuticals' Phase III REALIZE Results,2011-04-01 07:30:00-04:00,VRTX,neutral
1327955.0,Vertex Data From Phase 3 Studies Showed Substantial Improvements in SVR Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C,2011-03-31 12:46:00-04:00,VRTX,positive
1327956.0,Vertex Pharmaceuticals Announces Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful   ,2011-03-31 10:10:00-04:00,VRTX,positive
1327957.0,Piper Jaffray Reiterates Overweight on Vertex Pharmaceuticals (VRTX),2011-03-31 09:18:00-04:00,VRTX,negative
1327958.0,Piper Jaffray Comments On EASL Meeting With Vertex,2011-03-31 07:43:00-04:00,VRTX,neutral
1327959.0,A Peek Into The Market Before The Trading Starts,2011-03-31 07:20:00-04:00,VRTX,neutral
1327960.0,"Vertex Announces Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C   ",2011-03-31 07:00:00-04:00,VRTX,neutral
1327961.0,"Vertex Phase 3 Data: Absolute Improvement +12.5% Vs. Placebo, No Discountinuations (VRTX)",2011-03-29 07:34:00-04:00,VRTX,positive
1327962.0,Vertex Pharmaceuticals Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function and Other Measures of Disease   ,2011-03-29 07:31:00-04:00,VRTX,positive
1327963.0,Goldman Sachs Comments On Management Meetings With Vertex Pharmaceuticals,2011-03-25 08:32:00-04:00,VRTX,neutral
1327964.0,J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX),2011-03-24 08:44:00-04:00,VRTX,neutral
1327965.0,Vertex Pharmaceuticals Announces That 15 abstracts on Company's Medicines in Development for Hepatitis C Were Accepted for Presentation at EASL Annual Meeting ,2011-03-07 08:19:00-05:00,VRTX,positive
1327966.0,Piper Jaffray Comments On Share Surge For Vertex Pharmaceuticals,2011-03-07 07:43:00-05:00,VRTX,positive
1327967.0,"Benzinga's Top ETF Decliners, March 3rd (EDZ, SQQQ, TYP, VXX)",2011-03-03 19:01:00-05:00,VRTX,positive
1327968.0,"Benzinga's Top ETF Gainers, March 3rd (TNA, TQQQ, EDC, FAS)",2011-03-03 18:43:00-05:00,VRTX,positive
1327969.0,Citi Reports VX-770 Is Helping Investors Breathe Easier For Vertex Pharmaceuticals,2011-03-03 10:38:00-05:00,VRTX,positive
1327970.0,Citigroup Raises PT On Vertex Pharmaceuticals To $51,2011-03-03 07:44:00-05:00,VRTX,neutral
1327971.0,Vertex Pharmaceuticals Presents Positive Phase 2 Interim Data from First Study of Telaprevir ,2011-03-02 12:01:00-05:00,VRTX,positive
1327972.0,Wedbush Upgrades Vertex Pharmaceuticals to Outperform,2011-02-24 12:09:00-05:00,VRTX,neutral
1327973.0,Goldman Sachs Suggest Buying Calls on Vertex Pharmaceuticals (VRTX),2011-02-24 09:20:00-05:00,VRTX,neutral
1327974.0,"Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash (WCRX, VRTX, ENDP, UTHR)",2011-02-24 02:44:00-05:00,VRTX,positive
1327975.0,Vertex Pharmaceuticals Announce Results From STRIVE And Discover Trials,2011-02-23 11:06:00-05:00,VRTX,neutral
1327976.0,Options Brief: Vertex Pharmaceuticals (VRTX),2011-02-23 10:32:00-05:00,VRTX,neutral
1327977.0,"Benzinga's Volume Movers (VRTX, NDSN, OCLR, GRMN)",2011-02-23 10:27:00-05:00,VRTX,neutral
1327978.0,J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX),2011-02-23 09:57:00-05:00,VRTX,neutral
1327979.0,"Benzinga's Top Pre-Market NASDAQ Gainers (VRTX, OCLR, JASO, AMAT)",2011-02-23 08:14:00-05:00,VRTX,positive
1327980.0,"J.P. Morgan Reiterates Vertex Neutral, Maintains $43 PT (VRTX)",2011-02-22 08:22:00-05:00,VRTX,neutral
1327981.0,Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX),2011-02-09 09:38:00-05:00,VRTX,neutral
1327982.0,"Goldman Sachs Initiates Neutral Rating on Smid-Cap Biotech (UTHR, VRTX, AMLN)",2011-02-08 09:20:00-05:00,VRTX,neutral
1327983.0,Goldman Says Buy Vertex Pharmaceuticals Options (VRTX),2011-02-08 07:24:00-05:00,VRTX,neutral
1327984.0,Options Brief: Vertex Pharmaceuticals (VRTX),2011-02-07 13:19:00-05:00,VRTX,neutral
1327985.0,"Piper Jaffray Reiterates Vertex Pharmaceuticals Overweight, $48 PT (VRTX)",2011-02-04 09:01:00-05:00,VRTX,negative
1327986.0,J.P. Morgan Rasies Vertex Pharmaceuticals PT To $43 (VRTX),2011-02-04 08:19:00-05:00,VRTX,neutral
1327987.0,"J&J Disappoints, 2011 Outlook Weak - Analyst Blog",2011-01-25 11:31:00-05:00,VRTX,negative
1327988.0,"J&J Disappoints, 2011 Outlook Weak - Analyst Blog",2011-01-25 10:45:00-05:00,VRTX,negative
1327989.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 18:01:00-05:00,VRTX,neutral
1327990.0,Priority Review for Vertex HCV Drug - Analyst Blog,2011-01-21 17:40:00-05:00,VRTX,neutral
1327991.0,Vertex Expects an Eventful 2011 - Analyst Blog,2011-01-10 11:01:00-05:00,VRTX,neutral
1327992.0,Vertex Expects an Eventful 2011 - Analyst Blog,2011-01-10 10:45:00-05:00,VRTX,neutral
1327993.0,J.P. Morgan Maintains Neutral Rating On VRTX,2011-01-10 09:53:00-05:00,VRTX,neutral
1327994.0,J.P. Morgan Healthcare Confab: Live Blog,2011-01-10 07:54:00-05:00,VRTX,neutral
1327995.0,Priority Review for Merck's HCV Drug - Analyst Blog,2011-01-07 12:33:00-05:00,VRTX,neutral
1327996.0,Priority Review for Merck's HCV Drug - Analyst Blog,2011-01-07 12:00:00-05:00,VRTX,neutral
1327997.0,Piper Jaffray Overweight On Vertex Pharmaceuticals  (VRTX),2011-01-06 08:01:00-05:00,VRTX,negative
1327998.0,Biotech 2011 Kickoff Party: Investor Preview,2011-01-05 06:55:00-05:00,VRTX,positive
1327999.0,"Monday's Put/Call Ratio Leaders (PKX, GMXR, GRA, VRTX, SLB)",2010-12-20 12:32:00-05:00,VRTX,neutral
1328000.0,Options Brief: Vertex Pharmaceuticals (VRTX),2010-12-20 10:11:00-05:00,VRTX,neutral
1328001.0,Wells Fargo Resumes Coverage On VRTX With A $44-$48 Valuation Range,2010-12-10 10:51:00-05:00,VRTX,positive
1328002.0,Biotech Stock Mailbag: Amarin,2010-12-03 07:00:00-05:00,VRTX,neutral
1328003.0,Piper Jaffray On Vertex Pharmaceuticals,2010-12-01 09:16:00-05:00,VRTX,neutral
1328004.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 18:30:00-05:00,VRTX,positive
1328005.0,Vertex Eyes Telaprevir Approval - Analyst Blog,2010-11-24 13:01:00-05:00,VRTX,positive
1328006.0,Vertex Files for Hep C Drug Approval,2010-11-23 07:38:00-05:00,VRTX,positive
1328007.0,Loss Widens for Vertex - Analyst Blog,2010-10-28 18:48:00-04:00,VRTX,negative
1328008.0,"Some Lesser Known Popular ETFs (IVV, MDY, IJR)",2010-10-27 13:55:00-04:00,VRTX,positive
1328009.0,"From A Financial Perspective, Vertex Pharmaceuticals Q3 Is Uneventful",2010-10-26 09:35:00-04:00,VRTX,neutral
1328010.0,VRTX EPS In-Line With Estimates; Could Launch Blockbuster Drug in 2011,2010-10-26 08:57:00-04:00,VRTX,positive
1328011.0,Vertex Pharmaceuticals Posts Mixed Results (VRTX),2010-10-25 16:24:00-04:00,VRTX,neutral
1328012.0,Vertex Pharmaceuticals Reports Third Quarter Results; EPS ($.87) ,2010-10-25 16:19:00-04:00,VRTX,neutral
1328013.0,Vertex To Present Data On Recent Pharma Studies,2010-10-13 07:41:00-04:00,VRTX,neutral
1328014.0,"Coverage Initiated On: (EFX, GME, BBT, ECOL, VRTX)",2010-10-07 10:30:00-04:00,VRTX,neutral
1328015.0,Vertex Pharmaceuticals Announces Exercise of Underwriter's Option to Purchase Senior Notes (VRTX)   ,2010-09-24 08:03:00-04:00,VRTX,neutral
1328016.0,"Benzinga's Top Pre-Market NASDAQ Losers (CVVT, NOVL, TIVO, VRTX) ",2010-09-23 09:23:00-04:00,VRTX,negative
1328017.0,Vertex Pharmaceuticals Announces Proposed $375M Public Offering ,2010-09-22 16:06:00-04:00,VRTX,neutral
1328018.0,Oppenheimer's Current Biotech Ratings,2010-09-13 10:41:00-04:00,VRTX,neutral
1328019.0,Vertex's Telaprevir Encourages - Analyst Blog,2010-09-08 17:48:00-04:00,VRTX,positive
1328020.0,Vertex Reports Solid REALIZE Data,2010-09-08 09:05:00-04:00,VRTX,positive
1328021.0,Oppenheimer Sees 30% Upside In Vertex Pharmaceuticals (VRTX),2010-09-08 07:05:00-04:00,VRTX,neutral
1328022.0,"2H:10 Milestones In Drug Discovery (ARNA, VRTX, REGN, EXEL)",2010-08-18 11:28:00-04:00,VRTX,neutral
1328023.0,Oppenheimer Remains Buyer Of VRTX,2010-08-17 11:11:00-04:00,VRTX,neutral
1328024.0,Vertex Pharmaceuticals; Earnings Mixed (VRTX),2010-07-28 16:23:00-04:00,VRTX,neutral
1328025.0,Upside Purchased on Vertex Pharma (VRTX) ,2010-07-01 10:38:00-04:00,VRTX,neutral
1328026.0,Calls Purchased on Vertex Pharmaceuticals (VRTX),2010-06-30 12:02:00-04:00,VRTX,neutral
1328027.0,Piper Jaffray Retains Overweight Rating For Vertex Pharma (VRTX),2010-06-23 16:08:00-04:00,VRTX,negative
1328028.0,Mad Money Lightning Round: Cramer Prefers CRUS Over CREE,2010-06-21 08:40:00-04:00,VRTX,negative
1328029.0,"Mad Money Lightning Round: Cramer Gives His Opinion On VRTX, GMCR, SJM, CREE, STD, S, FAF, SPW",2010-06-19 17:01:00-04:00,VRTX,negative
1328030.0,Vertex Pharmaceuticals To Present at Two Investor Conferences (VRTX),2010-06-01 16:43:00-04:00,VRTX,neutral
1328031.0,Focus Shifts Back to Domestic Issues 05-26-2010,2010-05-26 14:53:00-04:00,VRTX,neutral
1328032.0,"Benzingas Volume Movers (VRTX, CETV, NAFC, RMBS)",2010-05-26 14:26:00-04:00,VRTX,neutral
1328033.0,Positive ADVANCE Phase III Data Should Act As A Catalyst For JNJ,2010-05-26 11:43:00-04:00,VRTX,positive
1328034.0,"Benzingas Top Pre-Market Gainers (CJBK, TSCM, SOLF, LTXC, VRTX)",2010-05-26 08:48:00-04:00,VRTX,positive
1328035.0,"Benzinga's After Hours Gainers (VRTX, EXC, VVUS)",2010-05-25 19:03:00-04:00,VRTX,neutral
1328036.0,VRTX Initiated With Market Perform At Wells Fargo,2010-05-14 06:46:00-04:00,VRTX,positive
1328037.0,VRTX Well Positioned To Capture Initial Paradigm Shift In Hep C Therapy,2010-04-09 13:19:00-04:00,VRTX,positive
1328038.0,"BIB, BIS: New Biotech 2x ProShares",2010-04-09 03:00:00-04:00,VRTX,neutral
1328039.0,ThinkEquity Rates Vertex Pharmaceuticals (VRTX) A Hold,2010-04-08 12:12:00-04:00,VRTX,neutral
1328040.0,Vertex Pharmaceuticals Incorporated (VRTX) Maintains Overweight Rating,2010-03-30 17:43:00-04:00,VRTX,negative
1328041.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,VRTX,positive
1328042.0,Investors Are Turning To Small and Mid Cap ETFs In 2010,2010-03-15 16:50:00-04:00,VRTX,neutral
1328043.0,"Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)",2010-03-09 20:09:00-05:00,VRTX,positive
1328044.0,"Jim Cramer Comments On PMCS, CSCO, VRTX, GILD, PAL",2010-03-03 19:32:00-05:00,VRTX,neutral
1328045.0,"Mike Huckman Is Watching VRTX, DNDN, HGSI",2010-03-03 19:06:00-05:00,VRTX,neutral
1328046.0,"Vertex Pharmaceuticals, Inc. (VRTX) Maintains Buy Rating",2010-02-05 15:17:00-05:00,VRTX,neutral
1328047.0,Vertex Pharmaceuticals Inc. (VRTX) Upgraded To Outperform,2010-02-01 12:04:00-05:00,VRTX,neutral
1328048.0,Strong Product Pipeline At VRTX,2010-02-01 11:03:00-05:00,VRTX,positive
1328049.0,Vertex Pharma (VRTX) To File For Hepatitis Drug Approval,2010-01-13 04:14:00-05:00,VRTX,positive
1328050.0,Vertex Expects a Net Loss of Less Than $650 Million for 2009 (VRT),2010-01-11 15:11:00-05:00,VRTX,negative
1328051.0,"Benzingas Top Downgrades (VRTX, V, CXO, BEXP, COG)",2010-01-05 09:31:00-05:00,VRTX,positive
1328052.0,Index Futures Surge As Bank Of America (BAC) Is Set To Repay $45 Billion Government Bail Out Fund,2009-12-03 07:47:00-05:00,VRTX,neutral
1328053.0,"Shafran Talks About His Tech Stock Picks With Barrons: PNR, ADS, TLVT, VRTX, CREE, AZPN",2009-11-23 10:31:00-05:00,VRTX,neutral
1328054.0,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)",2009-11-02 09:29:00-05:00,VRTX,neutral
1328055.0,"Fast Money Crew Like FTO, VRTX, BAC, DIS",2009-09-30 18:58:00-04:00,VRTX,positive
1328056.0,"TheFortuneFinancial.com Free Market Research on BVF, TTI, WTI, DRC, VRTX and SBIB",2009-08-10 07:33:00-04:00,VRTX,positive
